| S.no |
Heading Name |
Date |
Edit |
Delete |
| 1 |
Challenges and Opportunities |
2025-02-11 |
|
|
| 2 |
Kidney Stones |
2025-01-30 |
|
|
| 3 |
Applications of Radiation Physics |
2025-01-06 |
|
|
| 4 |
Ethical Committee Consent |
2024-12-13 |
|
|
| 5 |
SURGICAL TECHNIQUE: AUGMENTATION PLATING WITH OR WITHOUT BG |
2024-12-09 |
|
|
| 6 |
AUGMENTATION PLATING |
2024-12-09 |
|
|
| 7 |
Institutional Review Board (IRB) |
2024-11-21 |
|
|
| 8 |
Ethical Committe |
2024-11-21 |
|
|
| 9 |
Conflicts Of Intrest |
2024-10-23 |
|
|
| 10 |
CONFLICTS OF INTEREST |
2024-10-23 |
|
|
| 11 |
Data Sharing |
2024-10-22 |
|
|
| 12 |
Authors Declaration of Approval |
2024-10-22 |
|
|
| 13 |
Criteria for Inclusion in the Authors’ List |
2024-10-22 |
|
|
| 14 |
Previous Presentation of the Study |
2024-10-22 |
|
|
| 15 |
Initial Therapy |
2024-10-09 |
|
|
| 16 |
Limitations of the research |
2024-09-27 |
|
|
| 17 |
Anti-cancer Activity |
2024-09-05 |
|
|
| 18 |
Hyperlipidimic Activity |
2024-09-05 |
|
|
| 19 |
Anti-protozoal Activity |
2024-09-05 |
|
|
| 20 |
Anti-oxidant Activity |
2024-09-05 |
|
|
| 21 |
Anti-inflammatory Activity |
2024-09-05 |
|
|
| 22 |
Anti-helmnthic Activity |
2024-09-05 |
|
|
| 23 |
Anti-diabetic Activity |
2024-09-05 |
|
|
| 24 |
Artemisia roxburghiana |
2024-09-05 |
|
|
| 25 |
The Answers of the New Model, to the Questions Left Unanswered by the Standard Model |
2024-08-30 |
|
|
| 26 |
The New Model for the Subatomic Particles and the Fundamental Interactions |
2024-08-30 |
|
|
| 27 |
The Questions Set In Doubt the Standard Model Theory |
2024-08-30 |
|
|
| 28 |
The Standard Model |
2024-08-30 |
|
|
| 29 |
Settings of the Problem |
2024-07-11 |
|
|
| 30 |
Discrete Kalman Filter Algorithm |
2024-07-11 |
|
|
| 31 |
State Estimation and Nonlinear Filtering |
2024-07-11 |
|
|
| 32 |
Kalman Filter |
2024-07-11 |
|
|
| 33 |
Data Available |
2024-07-04 |
|
|
| 34 |
APPENDIX 4 |
2024-07-02 |
|
|
| 35 |
APPENDIX 3 |
2024-07-02 |
|
|
| 36 |
APPENDIX 2 |
2024-07-02 |
|
|
| 37 |
APPENDIX 1 – Problem Session |
2024-07-02 |
|
|
| 38 |
Chapter 8 Introduction to Self-Generating Primal Groups & Peano ´S Postulates to Generate the Prime Numbers |
2024-07-02 |
|
|
| 39 |
Chapter 7 Rules for Tables and Creating Tables |
2024-07-02 |
|
|
| 40 |
Chapter 6 Building Rppn Tables |
2024-07-02 |
|
|
| 41 |
Chapter 5 Physical Dimensions Of Sppn Tables |
2024-07-02 |
|
|
| 42 |
Chapter 4 Converting between Mod10 and Modnt Number Systems |
2024-07-02 |
|
|
| 43 |
Chapter 3 Notes on MODnt number system |
2024-07-02 |
|
|
| 44 |
Chapter 2 Creating sppn tables |
2024-07-02 |
|
|
| 45 |
Chapter 1 What the ancient greeks knew and what they did not know and what every mathematician since has failed to realize |
2024-07-02 |
|
|
| 46 |
Analysis of the Development Status of Mass Sports |
2024-07-01 |
|
|
| 47 |
Analysis of the Development Status of Mass Sports |
2024-07-01 |
|
|
| 48 |
Overview of Behavioral Economics Theory |
2024-07-01 |
|
|
| 49 |
The Explicit Formula for Stirling Numbers of the second kind |
2024-06-20 |
|
|
| 50 |
Relation between Bernoulli Numbers and Stirling Numbers of the Second Kind |
2024-06-11 |
|
|
| 51 |
Stirling Numbers of the Second Kind |
2024-06-11 |
|
|
| 52 |
Annexes |
2024-06-03 |
|
|
| 53 |
Main Property of the Surjection |
2024-06-03 |
|
|
| 54 |
The "Theory of the Chain Reaction" and the "New Model" for The Subatomic Particles and Fundamental Interactions (A New Attempt to Explain the Creation of the Cosmos) |
2024-05-07 |
|
|
| 55 |
Recapitulation of the Established Views of Science on the Creation and the Functioning of the Universe |
2024-05-06 |
|
|
| 56 |
The General Theory of Relativity and the Explanation of the Interaction of Gravity |
2024-05-06 |
|
|
| 57 |
The Completion of the Big Bang Theory by the Standard Model Theory |
2024-05-06 |
|
|
| 58 |
The New Age and the Big Bang Theory |
2024-05-06 |
|
|
| 59 |
The Renaissance and the Heliocentric System |
2024-05-06 |
|
|
| 60 |
The Middle Ages |
2024-05-06 |
|
|
| 61 |
The First Scientific Explanations and the Geocentric System |
2024-05-06 |
|
|
| 62 |
The Knowledge of the Primitive Man, The Mythology and the Religions |
2024-05-06 |
|
|
| 63 |
Conclusion by Scientific Hypothesis |
2024-05-02 |
|
|
| 64 |
Homogeneous Riemannian Manifolds with Applications to Primes |
2024-05-02 |
|
|
| 65 |
Preliminaries |
2024-04-29 |
|
|
| 66 |
Source |
2024-04-05 |
|
|
| 67 |
Time in UPL Model |
2024-03-01 |
|
|
| 68 |
Black Holes with Schwarzschild Radius |
2024-03-01 |
|
|
| 69 |
Distortion in Space Caused by Antiuholes |
2024-03-01 |
|
|
| 70 |
Model UPL Related To General Relativity |
2024-03-01 |
|
|
| 71 |
Multiple Representations of The UPL Model |
2024-03-01 |
|
|
| 72 |
Calculations of Pressures And Forces On The UPL Model |
2024-03-01 |
|
|
| 73 |
Gravitational Forces On The UPL Model |
2024-03-01 |
|
|
| 74 |
UPL Model |
2024-03-01 |
|
|
| 75 |
Mass Annihilation |
2024-03-01 |
|
|
| 76 |
Negative Mass |
2024-03-01 |
|
|
| 77 |
CASE DETAILS ATTACHED |
2024-03-01 |
|
|
| 78 |
Sensitivity Analysis |
2024-02-05 |
|
|
| 79 |
OC problem for S-I-R Model |
2024-02-05 |
|
|
| 80 |
Description of the Sir Epidemic Model |
2024-02-05 |
|
|
| 81 |
Related Studies |
2024-02-05 |
|
|
| 82 |
Competing Interests Statement |
2024-01-04 |
|
|
| 83 |
Availability of Data |
2024-01-03 |
|
|
| 84 |
Publication Consent |
2023-11-20 |
|
|
| 85 |
Funding and Conflict of Interest |
2023-11-09 |
|
|
| 86 |
Author-Contributions |
2023-11-08 |
|
|
| 87 |
Physiotherapy Management |
2023-10-13 |
|
|
| 88 |
Stages of Fasciotomy |
2023-10-13 |
|
|
| 89 |
Layers of Skin |
2023-10-13 |
|
|
| 90 |
Current Trends in Compartment Syndrome |
2023-10-13 |
|
|
| 91 |
Compartment Syndrome |
2023-10-13 |
|
|
| 92 |
Future Research Recommendations |
2023-10-10 |
|
|
| 93 |
Using ICAR |
2023-10-04 |
|
|
| 94 |
Building ICAR |
2023-10-04 |
|
|
| 95 |
Retail Spc Data Space Ad Its Transformation |
2023-09-29 |
|
|
| 96 |
Formulation Of Retailing Elements |
2023-09-29 |
|
|
| 97 |
Energy balance |
2023-09-23 |
|
|
| 98 |
Annex a1 |
2023-09-20 |
|
|
| 99 |
Part 2 |
2023-09-11 |
|
|
| 100 |
Part 1 |
2023-09-11 |
|
|
| 101 |
Data Sharing Statement |
2023-09-02 |
|
|
| 102 |
Life Science Reporting |
2023-08-28 |
|
|
| 103 |
Grant Support Details |
2023-08-28 |
|
|
| 104 |
Calculation of g |
2023-08-09 |
|
|
| 105 |
Equation for g |
2023-08-09 |
|
|
| 106 |
Presentation at a Meeting |
2023-08-08 |
|
|
| 107 |
Strength |
2023-08-05 |
|
|
| 108 |
A value for α |
2023-08-04 |
|
|
| 109 |
Application to the photon gas |
2023-08-04 |
|
|
| 110 |
The hamiltonian operator |
2023-08-04 |
|
|
| 111 |
Complex Numbers of Riemann Hypothesis |
2023-07-31 |
|
|
| 112 |
Introduction(Section 1) |
2023-07-31 |
|
|
| 113 |
References (Section 12) |
2023-07-26 |
|
|
| 114 |
Software Availability (Section 11) |
2023-07-26 |
|
|
| 115 |
Acknowledgements (Section 10) |
2023-07-26 |
|
|
| 116 |
Abbreviations (Section 9) |
2023-07-26 |
|
|
| 117 |
Appendix (8) |
2023-07-26 |
|
|
| 118 |
Conclusion (Section 7) |
2023-07-26 |
|
|
| 119 |
Potential benefits of a new Mathematics as an Amalgamation of IC as a Foundation for Intelligence and IC as a Foundation for Mathematics (Section 7) |
2023-07-26 |
|
|
| 120 |
Potential benefits of a new Mathematics as an Amalgamation of â??IC as a Foundation for Intelligenceâ?? and â??IC as a Foundation for Mathematicsâ?? (Section 7) |
2023-07-26 |
|
|
| 121 |
Potential benefits of a new Mathematics as an Amalgamation of â??IC as a Foundation for Intelligenceâ?? and â??IC as a Foundation for Mathematicsâ?? (Section 7) |
2023-07-26 |
|
|
| 122 |
Potential benefits of a new Mathematics as an Amalgamation of &Lsquo;Ic as a Foundation for Intelligence&Rsquo; and &Lsquo;Ic as a Foundation for Mathematics&Rsquo; (Section 7) |
2023-07-26 |
|
|
| 123 |
How six other variants of ICMUP may be modelled via the SPMA concept (Section 6) |
2023-07-26 |
|
|
| 124 |
The SPMA Concept as a Variant of ICMUP (Section 5) |
2023-07-26 |
|
|
| 125 |
IC Via ICMUP (Section 4) |
2023-07-26 |
|
|
| 126 |
The SP-Multiple-Alignment Concept (Section 3) |
2023-07-26 |
|
|
| 127 |
A Bare-Bones Introduction to the SPTI (Section 2) |
2023-07-26 |
|
|
| 128 |
Challenges and future directions |
2023-07-11 |
|
|
| 129 |
Data sharing agreement |
2023-07-11 |
|
|
| 130 |
Acknowlegement |
2023-07-06 |
|
|
| 131 |
Theorem |
2023-07-06 |
|
|
| 132 |
The Barycenter |
2023-07-06 |
|
|
| 133 |
Experimental Steps |
2023-07-03 |
|
|
| 134 |
Light: Particle or Wave? |
2023-06-27 |
|
|
| 135 |
The Energy Force |
2023-06-27 |
|
|
| 136 |
Trap sim ii |
2023-06-26 |
|
|
| 137 |
Stroboscopic exponentiation algorithm |
2023-06-26 |
|
|
| 138 |
Classical quantum-simulation algorithms |
2023-06-26 |
|
|
| 139 |
Cryptographical Properties of the Sequence |
2023-06-26 |
|
|
| 140 |
Description of Pseudo Random Bit Generator using DLFSR |
2023-06-26 |
|
|
| 141 |
Technical Preliminaries |
2023-06-26 |
|
|
| 142 |
Model Description |
2023-06-23 |
|
|
| 143 |
Lamp Description |
2023-06-23 |
|
|
| 144 |
Data Collection And Outcomes |
2023-06-20 |
|
|
| 145 |
Eligibility Criteria |
2023-06-20 |
|
|
| 146 |
Study design and Participants |
2023-06-20 |
|
|
| 147 |
Bell’s theorem |
2023-06-20 |
|
|
| 148 |
Bellâ??s theorem |
2023-06-20 |
|
|
| 149 |
The bell experiment |
2023-06-20 |
|
|
| 150 |
Ion trap quantum computers |
2023-06-20 |
|
|
| 151 |
Application |
2023-06-16 |
|
|
| 152 |
Main result |
2023-06-16 |
|
|
| 153 |
INTERPRETATION OF SCORES |
2023-06-15 |
|
|
| 154 |
DEVICE DESCRIPTION |
2023-06-15 |
|
|
| 155 |
Explanation of Test Results II |
2023-06-12 |
|
|
| 156 |
Explanation of Test Results I |
2023-06-12 |
|
|
| 157 |
Data Normalization |
2023-06-12 |
|
|
| 158 |
Data and Variables |
2023-06-12 |
|
|
| 159 |
Identity Disorder |
2023-06-08 |
|
|
| 160 |
Numerical Example |
2023-06-05 |
|
|
| 161 |
Design Method of Minimum-Phase Stabilizing Controllers |
2023-06-05 |
|
|
| 162 |
Properties of the Control System |
2023-06-05 |
|
|
| 163 |
The Parameterization of all Stabilizing Minimum-Phase Controllers for Minimum-Phase Strictly Proper Plants |
2023-06-05 |
|
|
| 164 |
Discussion & finding of study |
2023-06-01 |
|
|
| 165 |
Research questions |
2023-06-01 |
|
|
| 166 |
Acknowledgement/Funding |
2023-05-30 |
|
|
| 167 |
Contribution to Knowledge |
2023-05-30 |
|
|
| 168 |
Study objectives |
2023-05-12 |
|
|
| 169 |
Conclusion and Scope for Future Work |
2023-04-27 |
|
|
| 170 |
Comparison |
2023-04-27 |
|
|
| 171 |
Hyperparameters |
2023-04-27 |
|
|
| 172 |
Different Techniques Used |
2023-04-27 |
|
|
| 173 |
Data Preparation |
2023-04-27 |
|
|
| 174 |
List of Features Used in Modelling |
2023-04-27 |
|
|
| 175 |
Notations |
2023-04-27 |
|
|
| 176 |
Related Research |
2023-04-27 |
|
|
| 177 |
Author Declaration |
2023-04-26 |
|
|
| 178 |
Interpretation |
2023-04-26 |
|
|
| 179 |
Results Summary and Analysis |
2023-04-24 |
|
|
| 180 |
Research |
2023-04-24 |
|
|
| 181 |
Creating a Digital Game-Based Learning Game Focused on Arithmetic Training |
2023-04-24 |
|
|
| 182 |
CASE NO. 2 |
2023-04-12 |
|
|
| 183 |
CASE NO. 1 |
2023-04-12 |
|
|
| 184 |
The Clinical Outcomes |
2023-04-05 |
|
|
| 185 |
Termination Of Injection |
2023-04-05 |
|
|
| 186 |
Cement Mixing & Injection |
2023-04-05 |
|
|
| 187 |
Transpedicular Approach |
2023-04-05 |
|
|
| 188 |
Postoperative Evaluation |
2023-04-05 |
|
|
| 189 |
Numerical Simulations |
2023-04-05 |
|
|
| 190 |
Sensitivity Analysis of R0 |
2023-04-05 |
|
|
| 191 |
Stability Analysis |
2023-04-05 |
|
|
| 192 |
Model Formulation and Description |
2023-04-05 |
|
|
| 193 |
Choosing the Right Reference Frame |
2023-03-28 |
|
|
| 194 |
Molecular Dynamics Simulation Analysis Of Pd1 And One Of Its Hit Compounds |
2023-03-24 |
|
|
| 195 |
Mandible-First Approach And Maxilla-First Approach |
2023-03-23 |
|
|
| 196 |
Single-Splint Technique And Double-Splint Technique |
2023-03-23 |
|
|
| 197 |
Surgical Planning |
2023-03-23 |
|
|
| 198 |
Orthodontic Treatment |
2023-03-23 |
|
|
| 199 |
Clinical Studies |
2023-03-23 |
|
|
| 200 |
Socket Shield Technique |
2023-03-23 |
|
|
| 201 |
Treatment And Prognosis |
2023-03-23 |
|
|
| 202 |
Histopathological Features |
2023-03-23 |
|
|
| 203 |
Clinical And Radiographic Features |
2023-03-23 |
|
|
| 204 |
Smokeless (Chewing) Tobacco |
2023-03-23 |
|
|
| 205 |
Smoked Tobacco |
2023-03-23 |
|
|
| 206 |
Surface Treatments |
2023-03-23 |
|
|
| 207 |
Polymerisation Cycle |
2023-03-23 |
|
|
| 208 |
Mixing Ratios |
2023-03-23 |
|
|
| 209 |
Solubility Of Base Material By-products |
2023-03-23 |
|
|
| 210 |
Methods and Results |
2023-03-22 |
|
|
| 211 |
The Thermodynamical Relation |
2023-03-13 |
|
|
| 212 |
Solution of Field Equations |
2023-03-13 |
|
|
| 213 |
The Metric and Basic Equations |
2023-03-13 |
|
|
| 214 |
Sources of Support |
2023-03-08 |
|
|
| 215 |
Adrenal Insufficiency |
2023-03-04 |
|
|
| 216 |
Adrenal Gland Hormones |
2023-03-04 |
|
|
| 217 |
Patient Consent for Publication |
2023-03-01 |
|
|
| 218 |
Conclusion and Discussion |
2023-02-28 |
|
|
| 219 |
APPLICATIONS OF HERBAL MEDICINE |
2023-02-27 |
|
|
| 220 |
HERBAL MEDICINE LOADED NATURAL POLYMER |
2023-02-27 |
|
|
| 221 |
SYNTHESIS OF POLYMER LOADED WITH HERBAL MEDICINE |
2023-02-27 |
|
|
| 222 |
METHODS FOR ASSESSING NUTRITIONAL STATUS IN CANCER CHILDREN |
2023-02-25 |
|
|
| 223 |
BIOMATERIALS COMBINED WITH REGENERATIVE MEDICINE |
2023-02-25 |
|
|
| 224 |
Objectives and methods |
2023-02-23 |
|
|
| 225 |
Implication Of Study |
2023-02-23 |
|
|
| 226 |
Study Duration |
2023-02-23 |
|
|
| 227 |
Sample Size |
2023-02-23 |
|
|
| 228 |
PROPOSED NEXT STEPS |
2023-02-22 |
|
|
| 229 |
EVALUATION OF THE STUDY |
2023-02-22 |
|
|
| 230 |
CLINICAL EVIDENCE SUMMARY OF STUDY |
2023-02-22 |
|
|
| 231 |
Conflicts Of Interest Statement |
2023-02-22 |
|
|
| 232 |
Nomenclature |
2023-02-15 |
|
|
| 233 |
CJG in the Pm Knowledge Space |
2023-02-15 |
|
|
| 234 |
Pmg and Its Knowledge Analysis |
2023-02-15 |
|
|
| 235 |
Clinical Message |
2023-02-13 |
|
|
| 236 |
Consent of Participate |
2023-02-13 |
|
|
| 237 |
Keypoints |
2023-02-13 |
|
|
| 238 |
Acknowledgment And Funding |
2023-02-09 |
|
|
| 239 |
Stages Of Non-Hodgkin Lymphomas |
2023-02-07 |
|
|
| 240 |
Diagnosis And Tests |
2023-02-07 |
|
|
| 241 |
Characteristics |
2023-02-07 |
|
|
| 242 |
Other White Blood Cells: Monocytes And Lymphocytes |
2023-02-07 |
|
|
| 243 |
Granulocytes: Neutrophils, Eosinophils And Basophils |
2023-02-07 |
|
|
| 244 |
Erythrocytes |
2023-02-07 |
|
|
| 245 |
Bone Marrow And Hematopoiesis |
2023-02-07 |
|
|
| 246 |
Transfusion Recipient Molecular Typing |
2023-02-07 |
|
|
| 247 |
Blood Donor Molecular Typing |
2023-02-07 |
|
|
| 248 |
The Effect of Elimination On Human Being |
2023-02-07 |
|
|
| 249 |
Malthusian Trap and The Economic Growth |
2023-02-07 |
|
|
| 250 |
Fundamental Elimination Mechanism |
2023-02-07 |
|
|
| 251 |
Basic Relation between Resource and Population |
2023-02-07 |
|
|
| 252 |
Dispersion Polymerization Techniques For The Fabrication of Polymeric Nanoparticles For Biomedical Applications |
2023-02-07 |
|
|
| 253 |
Fabrication Of Polymeric Nanoparticles |
2023-02-07 |
|
|
| 254 |
Advantages Of Nanoparticles |
2023-02-07 |
|
|
| 255 |
Classifications |
2023-02-06 |
|
|
| 256 |
Classifications |
2023-02-06 |
|
|
| 257 |
CELLULOSE - CHITOSAN FUNCTIONAL BIOCOMPOSITES |
2023-02-06 |
|
|
| 258 |
CELLULOSEâ??CHITOSAN FUNCTIONAL BIOCOMPOSITES |
2023-02-06 |
|
|
| 259 |
Abbreviation: |
2023-02-03 |
|
|
| 260 |
Evaluation phase |
2023-02-03 |
|
|
| 261 |
Material Methods |
2023-02-03 |
|
|
| 262 |
Data interpretation |
2023-01-25 |
|
|
| 263 |
DEPOSITIONAL SETTING |
2023-01-25 |
|
|
| 264 |
LIGAMENTS INVOLVED & MECHANISM OF INJURY |
2023-01-23 |
|
|
| 265 |
Data collection and measures |
2023-01-23 |
|
|
| 266 |
Exclusion criteria were as follows |
2023-01-23 |
|
|
| 267 |
Findings and discussion |
2023-01-10 |
|
|
| 268 |
Organic nanoparticles |
2023-01-10 |
|
|
| 269 |
The Author |
2023-01-10 |
|
|
| 270 |
Remarks |
2023-01-09 |
|
|
| 271 |
Effect of nanoparticles on different organs |
2023-01-09 |
|
|
| 272 |
Routes of human body adsorption of nanoparticles |
2023-01-09 |
|
|
| 273 |
ORGANIC NANOPARTICLES |
2023-01-09 |
|
|
| 274 |
Inorganic nanoparticles |
2023-01-09 |
|
|
| 275 |
Nanoparticles as antibiotic agents |
2023-01-09 |
|
|
| 276 |
Nanomaterial-induced OS measurement |
2023-01-09 |
|
|
| 277 |
Oxidative stress |
2023-01-09 |
|
|
| 278 |
Developing sustainable antimicrobials |
2023-01-09 |
|
|
| 279 |
Role of Genome |
2023-01-09 |
|
|
| 280 |
Role of evolution |
2023-01-09 |
|
|
| 281 |
Evolutionary adaptation and physiological acclimatisation |
2023-01-09 |
|
|
| 282 |
HISTOPATHOLOGY FINDING |
2023-01-06 |
|
|
| 283 |
Proof of Theorem |
2023-01-05 |
|
|
| 284 |
Wheat |
2023-01-03 |
|
|
| 285 |
SOLUTIONS TO AVOID THE CONS |
2022-12-22 |
|
|
| 286 |
CONS |
2022-12-22 |
|
|
| 287 |
WHY IS SOURDOUGH BETTER THAN OTHER BREAD? |
2022-12-22 |
|
|
| 288 |
SCIENCE BEHIND SOURDOUGH |
2022-12-22 |
|
|
| 289 |
METABOLISM |
2022-12-22 |
|
|
| 290 |
HORMONES |
2022-12-22 |
|
|
| 291 |
Methodology and Research Questions |
2022-12-19 |
|
|
| 292 |
Literature on the Public Perceptions of Nanotechnology |
2022-12-19 |
|
|
| 293 |
CONCLUDING NOTES AND FUTURE PROSPECTS |
2022-12-19 |
|
|
| 294 |
CYCLODEXTRIN BASED NANOSPONGES |
2022-12-19 |
|
|
| 295 |
Measurement of Variables |
2022-12-17 |
|
|
| 296 |
Statements and Declarations |
2022-12-16 |
|
|
| 297 |
pesticides |
2022-12-15 |
|
|
| 298 |
alteration of crops and biotechnology |
2022-12-15 |
|
|
| 299 |
the origin and scope |
2022-12-15 |
|
|
| 300 |
control methods |
2022-12-15 |
|
|
| 301 |
agribusiness |
2022-12-15 |
|
|
| 302 |
quantification |
2022-12-15 |
|
|
| 303 |
Prime Number DAC |
2022-12-15 |
|
|
| 304 |
Polygonal Number DAC |
2022-12-15 |
|
|
| 305 |
NANOPARTICLE TYPES |
2022-12-14 |
|
|
| 306 |
NANOTECHNOLOGY IN MEDICINE |
2022-12-14 |
|
|
| 307 |
BLOOD COAGULATION STUDY |
2022-12-09 |
|
|
| 308 |
DETECTION OF IN-VITRO INDUCED PLATELET AGGREGATES |
2022-12-09 |
|
|
| 309 |
PLATELET AGGREGATION TEST (WU AND HOAK, 1974) |
2022-12-09 |
|
|
| 310 |
HAEMATOLOGICAL ANALYSIS USING AUTOMATED MACHINE |
2022-12-09 |
|
|
| 311 |
ANIMAL SACRIFICE AND BLOOD SAMPLE COLLECTION |
2022-12-09 |
|
|
| 312 |
ANIMAL SACRIFICE AND BLOOD SAMPLE COLLECTIONc |
2022-12-09 |
|
|
| 313 |
ADMINISTRATION OF ASPIRIN (ACETYLSALICYLIC ACID) |
2022-12-09 |
|
|
| 314 |
EXTRACTION AND ADMINISTRATION OF ALLIUM CEPA |
2022-12-09 |
|
|
| 315 |
EXPERIMENTAL ANIMALS |
2022-12-09 |
|
|
| 316 |
PROCUREMENT OF ALLIUM CEPA |
2022-12-09 |
|
|
| 317 |
STUDY SITE |
2022-12-09 |
|
|
| 318 |
MATERIALS AND REAGENTS |
2022-12-09 |
|
|
| 319 |
OBJECTIVES OF THE STUDY |
2022-12-09 |
|
|
| 320 |
HYPOTHESIS |
2022-12-09 |
|
|
| 321 |
RATIONLAE OF STUDY |
2022-12-09 |
|
|
| 322 |
STATEMENT OF PROBLEM |
2022-12-09 |
|
|
| 323 |
CONCLUSION |
2022-12-08 |
|
|
| 324 |
Follow up |
2022-12-07 |
|
|
| 325 |
β-THALASSEMIA |
2022-12-07 |
|
|
| 326 |
#946;-THALASSEMIA |
2022-12-07 |
|
|
| 327 |
α- THALASSEMIA |
2022-12-07 |
|
|
| 328 |
SCREENING MEASURES TO PROTECT THE RECIPIENT |
2022-12-07 |
|
|
| 329 |
MEASURES TO PROTECT THE DONOR |
2022-12-07 |
|
|
| 330 |
APPLICATIONS IN VARIOUS FIELDS |
2022-12-06 |
|
|
| 331 |
SYNTHESIS: TOP-DOWN AND BOTTOM-UP APPROACHES |
2022-12-06 |
|
|
| 332 |
CLASSIFICATION OF NANOCELLULOSE |
2022-12-06 |
|
|
| 333 |
STRUCTURE AND PROPERTIES |
2022-12-06 |
|
|
| 334 |
Conclusion And Policy Recommendations |
2022-12-05 |
|
|
| 335 |
Estimation Results |
2022-12-05 |
|
|
| 336 |
Safety And Tolerability |
2022-11-29 |
|
|
| 337 |
Erosion And Abrasion Related To Tooth Bleaching |
2022-11-29 |
|
|
| 338 |
OSTEOPATHY TREATMENTS |
2022-11-29 |
|
|
| 339 |
Factors Related To Surgery |
2022-11-29 |
|
|
| 340 |
Analysis Method |
2022-11-29 |
|
|
| 341 |
Applications of nanomedicine |
2022-11-29 |
|
|
| 342 |
Applications of nanomedicine |
2022-11-29 |
|
|
| 343 |
Packaging sustainability improvement strategies |
2022-11-29 |
|
|
| 344 |
Applications of packaging materials |
2022-11-29 |
|
|
| 345 |
Applications of packaging materials |
2022-11-29 |
|
|
| 346 |
Types of packaging materials |
2022-11-29 |
|
|
| 347 |
Overview of new rice - oryza sativa l. |
2022-11-28 |
|
|
| 348 |
PREOPERATIVE ASSESSMENT |
2022-11-28 |
|
|
| 349 |
Genomic biomarkers for non-communicable diseases |
2022-11-24 |
|
|
| 350 |
Insufficiencies of modern medicine |
2022-11-24 |
|
|
| 351 |
Nanoparticle as a drug delivery agents in the treatment of CVDS |
2022-11-24 |
|
|
| 352 |
Nanoparticles for the treatment of heart diseases |
2022-11-24 |
|
|
| 353 |
Nanoparticles for the treatment of Coronary Artery Disease(CAD) |
2022-11-24 |
|
|
| 354 |
Complications Of Sub-Tenon’s Anesthesia |
2022-11-24 |
|
|
| 355 |
Advantages Of Sub-Tenon’s Anesthesia |
2022-11-24 |
|
|
| 356 |
Advantages Of Sub-Tenonâ??s Anesthesia |
2022-11-24 |
|
|
| 357 |
Sub-Tenon’s Block Technique |
2022-11-24 |
|
|
| 358 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 359 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 360 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 361 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 362 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 363 |
Advantages Of Sub-Tenonâ??s Anesthesia |
2022-11-24 |
|
|
| 364 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 365 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 366 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 367 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 368 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
| 369 |
Limitations In Point-Of-Care Tests |
2022-11-24 |
|
|
| 370 |
Platelet Function Monitoring |
2022-11-24 |
|
|
| 371 |
Standard-Bedside Coagulation Tests |
2022-11-24 |
|
|
| 372 |
Coagulation Cascade |
2022-11-24 |
|
|
| 373 |
Opioids |
2022-11-24 |
|
|
| 374 |
Local Anesthetic |
2022-11-24 |
|
|
| 375 |
Trigeminal Neuralgia |
2022-11-23 |
|
|
| 376 |
NANODRUGS |
2022-11-23 |
|
|
| 377 |
CURRENT CLINICAL PRACTICE OF USING PROBIOTICS IN AAD |
2022-11-23 |
|
|
| 378 |
ROLE PROBIOTICS IN PREVENTING ANTIBIOTICASSOCIATED DIARRHEA |
2022-11-23 |
|
|
| 379 |
ANTIBIOTIC-ASSOCIATED DIARRHEA |
2022-11-23 |
|
|
| 380 |
HERBAL TREATMENT APPROACHES |
2022-11-23 |
|
|
| 381 |
A Global snapshot of opportunities to incorporate nanomedicine education content |
2022-11-23 |
|
|
| 382 |
Coverage of Nanomedicine through pharmacy education |
2022-11-23 |
|
|
| 383 |
The influence of pre-existing antibodies on LAIV T- cell immunogenicity |
2022-11-22 |
|
|
| 384 |
Comparision of pre-clinical and clinical studies to find efficacy of LAIV |
2022-11-22 |
|
|
| 385 |
Comparision of Live Attenuated Influenza Vaccine (LAIV) with inactivated influenza vaccines |
2022-11-22 |
|
|
| 386 |
Nanodrugs |
2022-11-22 |
|
|
| 387 |
Modern Nanotechnology |
2022-11-22 |
|
|
| 388 |
History of Nanotechnology |
2022-11-22 |
|
|
| 389 |
HISTORY OF NANOTECHNOLOGY |
2022-11-22 |
|
|
| 390 |
Limitations of THz imaging methods |
2022-11-22 |
|
|
| 391 |
THz imaging methods |
2022-11-22 |
|
|
| 392 |
ENVIRONMENTAL HEALTH |
2022-11-18 |
|
|
| 393 |
Issues with Genome-Enabled EMRs |
2022-11-17 |
|
|
| 394 |
Keyword |
2022-11-16 |
|
|
| 395 |
CHEMICAL AND BIOLOGICAL EFFECTS OF AFLATOXINS |
2022-11-10 |
|
|
| 396 |
RISK ASSOCIATED WITH AFLATOXINS |
2022-11-10 |
|
|
| 397 |
AFLATOXIN CONTAMINATION PREVALENCE IN AGRICULTURAL PRODUCTS |
2022-11-10 |
|
|
| 398 |
CHARACTERISTICS OF AFLATOXINS |
2022-11-10 |
|
|
| 399 |
TYPES OF AFLATOXINS |
2022-11-10 |
|
|
| 400 |
PURPOSE OF THE STUDY |
2022-11-09 |
|
|
| 401 |
Etiology Diagnosis |
2022-11-09 |
|
|
| 402 |
PROBLEM STATEMENT |
2022-11-08 |
|
|
| 403 |
JUSTIFICATION |
2022-11-08 |
|
|
| 404 |
SOME COMMON USES OF MICROWAVE |
2022-10-29 |
|
|
| 405 |
MECHANISM OF MW-INDUCED HYPERTHERMIA |
2022-10-29 |
|
|
| 406 |
NORMAL AND MALIGNANT HUMAN TISSUE DIELECTRIC PROPERTIES |
2022-10-29 |
|
|
| 407 |
Limitation and Recommendations |
2022-10-28 |
|
|
| 408 |
Sample Availability |
2022-10-27 |
|
|
| 409 |
Data Availability Statement |
2022-10-27 |
|
|
| 410 |
Ethics Committee Statement |
2022-10-27 |
|
|
| 411 |
Author Agreement |
2022-10-27 |
|
|
| 412 |
Ethics Statement |
2022-10-27 |
|
|
| 413 |
Funding |
2022-10-27 |
|
|
| 414 |
Credit Authorship Contribution Statement |
2022-10-27 |
|
|
| 415 |
Acknowledgements (if any) |
2022-10-27 |
|
|
| 416 |
What this Study Adds |
2022-10-27 |
|
|
| 417 |
What is already known on this Topic |
2022-10-27 |
|
|
| 418 |
Resume |
2022-10-27 |
|
|
| 419 |
Outline |
2022-10-27 |
|
|
| 420 |
DISEASED SEEDLINGS |
2022-10-19 |
|
|
| 421 |
FUNGICIDE SEED TREATMENT |
2022-10-19 |
|
|
| 422 |
LOCAL AGROECOSYSTEM MODIFICATION |
2022-10-19 |
|
|
| 423 |
CASE B |
2022-10-14 |
|
|
| 424 |
CASE A |
2022-10-14 |
|
|
| 425 |
ARRHYTHMIAS AND TREATMENT |
2022-10-14 |
|
|
| 426 |
LINKING THE APPEARANCE OF A FUNGUS |
2022-10-13 |
|
|
| 427 |
Suggestions for Future Research |
2022-10-13 |
|
|
| 428 |
Discussion of Results |
2022-10-13 |
|
|
| 429 |
Periapical Bleeding |
2022-10-06 |
|
|
| 430 |
Regenerative Endodontics |
2022-10-06 |
|
|
| 431 |
Root Canal Fillings |
2022-10-06 |
|
|
| 432 |
Revascularization |
2022-10-06 |
|
|
| 433 |
Periodontopathogenic Biofilm |
2022-10-04 |
|
|
| 434 |
Oral Microbiomics |
2022-10-04 |
|
|
| 435 |
Oral Biofilms |
2022-10-04 |
|
|
| 436 |
Properties of Microbial Biofilms |
2022-10-04 |
|
|
| 437 |
Surface Decontamination |
2022-10-03 |
|
|
| 438 |
Infection and prevention control (IPC) |
2022-10-03 |
|
|
| 439 |
Differential Diagnosis |
2022-09-30 |
|
|
| 440 |
Follow-Up |
2022-09-30 |
|
|
| 441 |
Histopathology |
2022-09-30 |
|
|
| 442 |
FURTHER DISCUSSIONS AND CONSEQUENCES |
2022-09-23 |
|
|
| 443 |
STUDY METHODOLOGY |
2022-09-22 |
|
|
| 444 |
STUDY METHODOLOGY: |
2022-09-22 |
|
|
| 445 |
FEATURES OF THE INCLUDED STUDIES |
2022-09-21 |
|
|
| 446 |
Effects of the tongan volcanic aerosols |
2022-09-21 |
|
|
| 447 |
Terminal Illness |
2022-09-13 |
|
|
| 448 |
Discloures |
2022-09-13 |
|
|
| 449 |
Experimental Methods |
2022-09-12 |
|
|
| 450 |
Limitations and Recommendation |
2022-09-09 |
|
|
| 451 |
ANALYSIS AND PRESENTATION OF RESULTS |
2022-09-08 |
|
|
| 452 |
Ethical Clearance |
2022-09-07 |
|
|
| 453 |
Notification of Prior Presentation |
2022-09-07 |
|
|
| 454 |
Postoperative Care |
2022-08-29 |
|
|
| 455 |
Anaesthesia Technique |
2022-08-29 |
|
|
| 456 |
Conclusions and prospects for further research |
2022-08-18 |
|
|
| 457 |
Research results |
2022-08-18 |
|
|
| 458 |
Availability of the data |
2022-08-10 |
|
|
| 459 |
blication. CONFLICT OF INTEREST |
2022-08-05 |
|
|
| 460 |
SOURCE OF FINANCIAL GRANT |
2022-08-05 |
|
|
| 461 |
CONFLICT OF INTEREST |
2022-08-05 |
|
|
| 462 |
CONFLICT OF INTEREST |
2022-08-05 |
|
|
| 463 |
CONTRIBUTION OF AUTHORS |
2022-08-05 |
|
|
| 464 |
Neurostimulation and Peripheral Nerve Stimulation |
2022-08-03 |
|
|
| 465 |
Nerve Blocks, Rfa, Cryotherapy, Chemodenervation, Neurolysis |
2022-08-02 |
|
|
| 466 |
Interventional Pain Techniques For Cpps |
2022-08-01 |
|
|
| 467 |
Possible Mechanisms of Cpps |
2022-08-01 |
|
|
| 468 |
Biological Hazards |
2022-08-01 |
|
|
| 469 |
Brainstem and Basal Forebrain |
2022-08-01 |
|
|
| 470 |
Thalamus |
2022-08-01 |
|
|
| 471 |
Cerebral Cortex |
2022-08-01 |
|
|
| 472 |
Neuropathic Pain |
2022-08-01 |
|
|
| 473 |
Descending Pain Modulation |
2022-07-30 |
|
|
| 474 |
References |
2022-07-30 |
|
|
| 475 |
4. Acknowledgements |
2022-07-30 |
|
|
| 476 |
Conclusion |
2022-07-30 |
|
|
| 477 |
2. India |
2022-07-30 |
|
|
| 478 |
1. Background |
2022-07-30 |
|
|
| 479 |
References |
2022-07-30 |
|
|
| 480 |
Conclusion |
2022-07-30 |
|
|
| 481 |
4. Application Development |
2022-07-30 |
|
|
| 482 |
Result |
2022-07-30 |
|
|
| 483 |
2. EHR and EHR-S Evaluation Factors and Findings |
2022-07-30 |
|
|
| 484 |
Conclusion |
2022-07-30 |
|
|
| 485 |
8. Why Innovations do not Scale and the Way Forward |
2022-07-30 |
|
|
| 486 |
7. Digital Health Guidelines as a Framework for Futuristic Learning Health Systems |
2022-07-30 |
|
|
| 487 |
6. Digital Health Platforms as Early Warning Systems in Health Emergencies |
2022-07-30 |
|
|
| 488 |
5. Digital Platforms as Enablers for Universal Participation |
2022-07-30 |
|
|
| 489 |
4. Information as a Therapeutic Intervention for Achieving UHC |
2022-07-30 |
|
|
| 490 |
3. Information Asymmetries and its Impact on Health Systems |
2022-07-30 |
|
|
| 491 |
2. Current Strategies for Universal Health Coverage |
2022-07-30 |
|
|
| 492 |
Clinical Spectrum |
2022-07-29 |
|
|
| 493 |
Pathogenesis |
2022-07-29 |
|
|
| 494 |
Epidemiology and Risk Factors |
2022-07-29 |
|
|
| 495 |
Transmission |
2022-07-29 |
|
|
| 496 |
IMMUNOHISTOCHEMISTRY |
2022-07-28 |
|
|
| 497 |
LANGERHANS CELL HISTIOCYTOSIS |
2022-07-28 |
|
|
| 498 |
CHEMOPREVENTION |
2022-07-28 |
|
|
| 499 |
Primary Insufficiency of the Adrenal Glands |
2022-07-27 |
|
|
| 500 |
CASES |
2022-07-25 |
|
|
| 501 |
DATA AVAILABILITY STATEMENTS |
2022-07-25 |
|
|
| 502 |
Tooth Autotransplantation |
2022-07-25 |
|
|
| 503 |
Primary Root Canal Treatment |
2022-07-25 |
|
|
| 504 |
IMMUNITY AND COAGULATION |
2022-07-25 |
|
|
| 505 |
COLLECTION OF CLINICAL DATA |
2022-07-25 |
|
|
| 506 |
Modification of the gravity theory |
2022-07-23 |
|
|
| 507 |
Conclusions |
2022-07-22 |
|
|
| 508 |
GENE THERAPY |
2022-07-22 |
|
|
| 509 |
ALTERNATIVE THERAPIES |
2022-07-22 |
|
|
| 510 |
THE HEMOPHILIA REPLACEMENT THERAPY TARGETS |
2022-07-22 |
|
|
| 511 |
REPLACEMENT THERAPY |
2022-07-22 |
|
|
| 512 |
RED BLOOD CELL TRANSFUSION RECOMMENDATIONS |
2022-07-22 |
|
|
| 513 |
NANOMATERIALS IN THE FOOD INDUSTRY |
2022-07-21 |
|
|
| 514 |
NANOMATERIALS IN THE AGRIFOOD INDUSTRY |
2022-07-21 |
|
|
| 515 |
ETHICAL ISSUES |
2022-07-21 |
|
|
| 516 |
STANDARDS |
2022-07-21 |
|
|
| 517 |
TOXICITY TESTS AND CLINICAL TRIALS |
2022-07-21 |
|
|
| 518 |
MODELING |
2022-07-21 |
|
|
| 519 |
IMAGING |
2022-07-21 |
|
|
| 520 |
NANOINFORMATICS AREAS |
2022-07-21 |
|
|
| 521 |
NANOTECHNOLOGY AND NANOINFORMATICS |
2022-07-21 |
|
|
| 522 |
BIOMEDICAL INFORMATICS |
2022-07-21 |
|
|
| 523 |
NANOMATERIALS IN FOOD: TOXICOLOGICAL ASPECTS |
2022-07-21 |
|
|
| 524 |
ACTIVE FOOD PACKAGING SYSTEMS |
2022-07-21 |
|
|
| 525 |
FOOD PACKAGING WITH NANOTECHNOLOGY |
2022-07-21 |
|
|
| 526 |
NANOTECHNOLOGY IN FOOD PROCESSING |
2022-07-21 |
|
|
| 527 |
FOOD APPLICATIONS WITH POTENTIAL |
2022-07-21 |
|
|
| 528 |
OPPORTUNITIES |
2022-07-21 |
|
|
| 529 |
PURIFICATION OF CARBON NANOTUBES |
2022-07-21 |
|
|
| 530 |
SYNTHESIS TECHNIQUES OF CARBON NANOTUBES |
2022-07-21 |
|
|
| 531 |
PROPERTIES |
2022-07-21 |
|
|
| 532 |
Summary conclusion |
2022-07-18 |
|
|
| 533 |
Results/Discussions |
2022-07-18 |
|
|
| 534 |
Problem-solving observable physics |
2022-07-18 |
|
|
| 535 |
Publication of speakers |
2022-07-18 |
|
|
| 536 |
Lesson |
2022-07-18 |
|
|
| 537 |
Recent Publications |
2022-07-18 |
|
|
| 538 |
Types of Stem Cells |
2022-07-14 |
|
|
| 539 |
APPLICATION AND VERIFICATION: RADIUS OF MATTER ELEMENTARY PARTICLE |
2022-07-12 |
|
|
| 540 |
DEDUCTION |
2022-07-11 |
|
|
| 541 |
Past Confeernce Report |
2022-07-11 |
|
|
| 542 |
Seismic Units and Facies |
2022-07-08 |
|
|
| 543 |
Seismic Units and Facies |
2022-07-08 |
|
|
| 544 |
Seismic Units and Facies |
2022-07-08 |
|
|
| 545 |
2.Conclusion |
2022-07-01 |
|
|
| 546 |
References |
2022-07-01 |
|
|
| 547 |
Conclusion |
2022-07-01 |
|
|
| 548 |
References |
2022-07-01 |
|
|
| 549 |
9. Funding |
2022-07-01 |
|
|
| 550 |
8. Disclosure |
2022-07-01 |
|
|
| 551 |
7. Conclusion |
2022-07-01 |
|
|
| 552 |
6. Dimensional Data Model |
2022-07-01 |
|
|
| 553 |
5. Data Warehouse |
2022-07-01 |
|
|
| 554 |
4. Advantages of the Relational Data Model |
2022-07-01 |
|
|
| 555 |
3. Predicate Logic and Set Theory |
2022-07-01 |
|
|
| 556 |
2.Relational Data Model |
2022-07-01 |
|
|
| 557 |
1.Introduction |
2022-07-01 |
|
|
| 558 |
VIRUS TROPISM AND PATHOGENESIS |
2022-06-30 |
|
|
| 559 |
CLINICAL SYMPTOMS |
2022-06-30 |
|
|
| 560 |
THE VIRUS, ITS ORIGINS AND EVOLUTION |
2022-06-30 |
|
|
| 561 |
CO-INFECTION BY MULTIPLE VIRUSE |
2022-06-30 |
|
|
| 562 |
VIRAL NUCLEIC ACID DETECTION |
2022-06-30 |
|
|
| 563 |
SEROLOGICAL ASSAYS |
2022-06-30 |
|
|
| 564 |
MOLECULAR SCREENING |
2022-06-30 |
|
|
| 565 |
Expansion By Infected Tick |
2022-06-30 |
|
|
| 566 |
Serology |
2022-06-30 |
|
|
| 567 |
Role of Intima |
2022-06-30 |
|
|
| 568 |
Past |
2022-06-30 |
|
|
| 569 |
INTRODUCTION |
2022-06-28 |
|
|
| 570 |
Skeletal Malformations |
2022-06-24 |
|
|
| 571 |
Natural clinical course |
2022-06-24 |
|
|
| 572 |
Vascular access and regional anesthesia |
2022-06-24 |
|
|
| 573 |
Airway Management |
2022-06-24 |
|
|
| 574 |
PERSPECTRIVE |
2022-06-23 |
|
|
| 575 |
ADRENAL GLAND |
2022-06-21 |
|
|
| 576 |
PITUITARY GLAND |
2022-06-21 |
|
|
| 577 |
CHEMICALS NEED TO BE AVOID |
2022-06-21 |
|
|
| 578 |
DICHOTOMOUS CLASSIFICATION (TAXONOMY) OF PSYCHOLOGICAL THEORIES |
2022-06-16 |
|
|
| 579 |
Publications |
2022-06-15 |
|
|
| 580 |
Suggestions/Recommendations |
2022-06-08 |
|
|
| 581 |
SYNTHETIC SEED PRODUCTION |
2022-05-31 |
|
|
| 582 |
CONCLUSIONS AND PERSPECTIVES |
2022-05-31 |
|
|
| 583 |
OXIDATIVE THF BREAKDOWN |
2022-05-31 |
|
|
| 584 |
THE ROLE OF NANOTECHNOLOGY IN IMMUNOTHERAPY IN HER2-POSITIVE BREAST CANCER |
2022-05-26 |
|
|
| 585 |
SMALL MOLECULE TYROSINE KINASE INHIBITORS (SMTKIS) |
2022-05-26 |
|
|
| 586 |
ANTIBODY DRUG CONJUGATES (ADCS) |
2022-05-26 |
|
|
| 587 |
PERTUZUMAB |
2022-05-26 |
|
|
| 588 |
LARGE MOLECULE TYROSINE KINASE INHIBITORS (TKI) |
2022-05-26 |
|
|
| 589 |
Analytical Methods |
2022-05-25 |
|
|
| 590 |
Observational Study |
2022-05-24 |
|
|
| 591 |
QUALITY CONTROL AND STATISTICAL ANALYSIS |
2022-05-21 |
|
|
| 592 |
INTERESTED OUTCOMES |
2022-05-21 |
|
|
| 593 |
SEARCHING THE LITERATURE AND CHOOSING A STUDY |
2022-05-21 |
|
|
| 594 |
PATHOLOGIC FINDINGS AND PATIENTS |
2022-05-21 |
|
|
| 595 |
THE TUMOR'S LOCALIZATION |
2022-05-20 |
|
|
| 596 |
REPRODUCTIVE AGING |
2022-05-20 |
|
|
| 597 |
YOUNG WOMEN'S REPRODUCTIVE AXIS |
2022-05-20 |
|
|
| 598 |
REASONS FOR THE SUMMIT ON DIABETES SURGERY |
2022-05-20 |
|
|
| 599 |
HOW TO MANAGE ANGER IN CHILDREN? |
2022-05-19 |
|
|
| 600 |
WHAT ARE THE REASONS BEHIND ANGER IN CHILDREN? |
2022-05-19 |
|
|
| 601 |
ANALYSIS ON DRUG DISCOVERY |
2022-05-16 |
|
|
| 602 |
Drug Delivery Technologies Pharmaceutical Delivery |
2022-05-13 |
|
|
| 603 |
Pharmaceutical Analysis and Developments |
2022-05-13 |
|
|
| 604 |
Drug Discovery and Development |
2022-05-13 |
|
|
| 605 |
DRUG TOXICOLOGY |
2022-05-13 |
|
|
| 606 |
DIFFERENT BACTERIAL STRAINS FOUND AS CONTAMINANTS IN MILK |
2022-05-12 |
|
|
| 607 |
PREPARATION OF REAL SAMPLES |
2022-05-11 |
|
|
| 608 |
Mechanisms mediating cell plasticity |
2022-05-11 |
|
|
| 609 |
POTENTIAL OPPORTUNITIES IN THE DENTAL SERVICES MARKET |
2022-05-09 |
|
|
| 610 |
DENTAL SERVICES MARKET SEGMENTATION |
2022-05-09 |
|
|
| 611 |
DENTAL SERVICES MARKET SIZE |
2022-05-09 |
|
|
| 612 |
DENTAL SERVICES MARKET COMPETITIVE LANDSCAPE |
2022-05-09 |
|
|
| 613 |
EXPERIMENTAL PART |
2022-05-09 |
|
|
| 614 |
Grant Information |
2022-05-06 |
|
|
| 615 |
HCV Proteins |
2022-05-06 |
|
|
| 616 |
Industrial trans-fatty acid intake and the risk of coronary heart disease |
2022-05-06 |
|
|
| 617 |
High Molecular Weight with Low Concentration Has an Impact on Immunity and Cancer |
2022-05-06 |
|
|
| 618 |
Higher Beta-Glucan Viscosity and Better Post-Prandial Glucose Metabolism |
2022-05-06 |
|
|
| 619 |
High Molecular Weight Beta-Glucan Contributes towards better Cholesterol Control and Better Cardiovascular Outcomes |
2022-05-06 |
|
|
| 620 |
Medications and multifunctional products with phosphatidylserine: A very well cognitive solution |
2022-05-06 |
|
|
| 621 |
REGULATING NANOROBOTS |
2022-05-05 |
|
|
| 622 |
Management During Pregnancy |
2022-05-04 |
|
|
| 623 |
Nanodentistry |
2022-05-04 |
|
|
| 624 |
Clinical Features |
2022-05-03 |
|
|
| 625 |
Pheochromocytoma |
2022-05-03 |
|
|
| 626 |
ONCOLOGY NURSING |
2022-05-02 |
|
|
| 627 |
UROGYNAECOLOGY |
2022-05-02 |
|
|
| 628 |
FEMALE AND GENITAL MUTILATION |
2022-05-02 |
|
|
| 629 |
TREATMENT FOR DIABETES |
2022-04-30 |
|
|
| 630 |
CVD RISK REDUCTION RESEARCH |
2022-04-30 |
|
|
| 631 |
LIPID RELATED DANGERS |
2022-04-30 |
|
|
| 632 |
POTENTIAL NANOROBOT HAZARDS |
2022-04-28 |
|
|
| 633 |
TECHNOLOGICAL DEVELOPMENT OF NANOROBOTS |
2022-04-28 |
|
|
| 634 |
BIOPSY |
2022-04-28 |
|
|
| 635 |
WOUND HEALING |
2022-04-28 |
|
|
| 636 |
TRANSPORT AND RELEASE OF CELLS |
2022-04-28 |
|
|
| 637 |
THERAPEUTIC AND IMAGING AGENTS FOR CANCER THERAPY |
2022-04-28 |
|
|
| 638 |
in vivo NANOROBOTIC APPLICATIONS |
2022-04-28 |
|
|
| 639 |
PREVENTIVE, COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY |
2022-04-25 |
|
|
| 640 |
DENTAL BIOMATERIALS AND BIOENGINEERING |
2022-04-25 |
|
|
| 641 |
Key Words: |
2022-04-19 |
|
|
| 642 |
Result |
2022-04-19 |
|
|
| 643 |
RBC MEMBRANE-COATED POLYMERIC NANOPARTICLES |
2022-04-13 |
|
|
| 644 |
RED BLOOD CELL (RBC)-BASED SYSTEMS AS LONG-CIRCULATING DRUG CARRIERS |
2022-04-13 |
|
|
| 645 |
CONCLUSION AND FUTURE OUTLOOK |
2022-04-13 |
|
|
| 646 |
ENGINEERED NANOPARTICLES |
2022-04-13 |
|
|
| 647 |
GENERAL PHARMACOKINETIC CHARACTERISTICS OF NANODRUGS |
2022-04-13 |
|
|
| 648 |
INTRODUCTION |
2022-04-13 |
|
|
| 649 |
PERSPECTIVES FOR THE FUTURE |
2022-04-13 |
|
|
| 650 |
RECENT DEVELOPMENTS |
2022-04-12 |
|
|
| 651 |
ONCOLOGY |
2022-04-12 |
|
|
| 652 |
HEMATOLOGY |
2022-04-12 |
|
|
| 653 |
MICROBIOLOGY |
2022-04-12 |
|
|
| 654 |
THE MECHANISM OF COFFEE’S HEPATOPROTECTIVE EFFECT |
2022-04-06 |
|
|
| 655 |
ABSTRACT |
2022-04-06 |
|
|
| 656 |
Keywords |
2022-04-06 |
|
|
| 657 |
COFFEE |
2022-04-06 |
|
|
| 658 |
RECOMMENDATION. |
2022-03-30 |
|
|
| 659 |
LITERATURE REVIEW. |
2022-03-30 |
|
|
| 660 |
AIM OF THE PAPER |
2022-03-30 |
|
|
| 661 |
Consent to Publication |
2022-03-22 |
|
|
| 662 |
AUTHOR’S INFORMATION |
2022-03-22 |
|
|
| 663 |
CLINICAL FEATURE |
2022-03-15 |
|
|
| 664 |
Key Words |
2022-03-10 |
|
|
| 665 |
Low Store and Amassing at the Cancer Locale and Serious After effects |
2022-03-04 |
|
|
| 666 |
Repair of Bone |
2022-02-28 |
|
|
| 667 |
Breast-Q |
2022-02-28 |
|
|
| 668 |
FUTURE ASPECTS |
2022-02-28 |
|
|
| 669 |
Nucleosides Can Be Phosphorylated By Explicit Kinases in the Cell, Delivering Nucleotides |
2022-02-25 |
|
|
| 670 |
Pyrrolysine Is Combined Into Specific Proteins at A UAG Codon |
2022-02-25 |
|
|
| 671 |
The Least Demanding Kind of Sugar Is a Monosaccharide |
2022-02-25 |
|
|
| 672 |
They Give the Plan of Cells and Play out An Extensive Parcel of the Limits Related with Life |
2022-02-25 |
|
|
| 673 |
Around 150 Quassinoids Have Been Separated Relies Upon Their Substance Structures |
2022-02-23 |
|
|
| 674 |
It is a Complex Organic Liquid, Which Helps in the Improvement of Resistance in the Infant |
2022-02-23 |
|
|
| 675 |
Characterizing Dietary Fiber is a Different Interaction and is Subject to Both Sustenance and Scientific Ideas |
2022-02-23 |
|
|
| 676 |
Cell Viability was Measured Using the MTT Assay |
2022-02-23 |
|
|
| 677 |
Inductively coupled plasma (ICP) arrangement |
2022-02-23 |
|
|
| 678 |
Decomposition and Analysis Data هه |
2022-02-22 |
|
|
| 679 |
Hypothesis Main |
2022-02-22 |
|
|
| 680 |
Common Language of All Nations Mathematics |
2022-02-22 |
|
|
| 681 |
Solution |
2022-02-22 |
|
|
| 682 |
Derivation of Modified Variational Iteration Method and Fourier series of Periodic Function with a Period 2 for Solving Non-Homogeneous Ordinary Differential Equations |
2022-02-22 |
|
|
| 683 |
Digital Waveguide Modeling of the Vocal Tract |
2022-02-22 |
|
|
| 684 |
Gibbs Sampling |
2022-02-22 |
|
|
| 685 |
Issues of Repeated Game |
2022-02-22 |
|
|
| 686 |
|
2022-02-21 |
|
|
| 687 |
To ensure the proper replication of cell additives and department |
2022-02-17 |
|
|
| 688 |
Chemotherapy is one of the essential categories of the medical area |
2022-02-17 |
|
|
| 689 |
Maximum oncogenes started as proto-oncogenes: normal genes involved in mobile growth |
2022-02-17 |
|
|
| 690 |
Vasculogenesis is the embryonic formation of endothelial cells |
2022-02-17 |
|
|
| 691 |
The technique involves extraction of pattern cells or tissues |
2022-02-17 |
|
|
| 692 |
ROLES AND RESPONSIBILITY |
2022-02-15 |
|
|
| 693 |
Model Development |
2022-02-09 |
|
|
| 694 |
Study Procedures |
2022-02-09 |
|
|
| 695 |
Ethical Committie |
2022-02-08 |
|
|
| 696 |
Statistical Analysis and Results |
2022-02-08 |
|
|
| 697 |
Conclusion |
2022-02-03 |
|
|
| 698 |
Abreviations |
2022-01-10 |
|
|
| 699 |
Result and Disscussion |
2022-01-10 |
|
|
| 700 |
Systematic Review Supports Value of Communication Skills and PPR |
2022-01-04 |
|
|
| 701 |
Methods of Bone Grafting |
2022-01-04 |
|
|
| 702 |
test |
2021-12-31 |
|
|
| 703 |
Informed Consent |
2021-12-30 |
|
|
| 704 |
Conflicts Of Interest |
2021-12-30 |
|
|
| 705 |
Compliance With Ethical Standards |
2021-12-30 |
|
|
| 706 |
The Subjective Nature of Dreams |
2021-12-29 |
|
|
| 707 |
Symptoms and Identification |
2021-12-27 |
|
|
| 708 |
Diagnosis and Treatment |
2021-12-27 |
|
|
| 709 |
Types |
2021-12-27 |
|
|
| 710 |
Causes and Symptoms |
2021-12-27 |
|
|
| 711 |
Osteosarcoma Treatment |
2021-12-23 |
|
|
| 712 |
Subtypes of Osteosarcoma |
2021-12-23 |
|
|
| 713 |
Rules for young researchers forum |
2021-12-16 |
|
|
| 714 |
Hematology Congress 2022 Young Scientist Awards |
2021-12-16 |
|
|
| 715 |
Why to join the event? |
2021-12-16 |
|
|
| 716 |
About Conference |
2021-12-16 |
|
|
| 717 |
Challenges Related to Water Management in Agriculture |
2021-12-14 |
|
|
| 718 |
Management of Alkaline Soil |
2021-12-13 |
|
|
| 719 |
Effect of Alkalinity on Physical and Chemical Properties of Soil |
2021-12-13 |
|
|
| 720 |
Soil Alkalinity and Sources of Alkalinity |
2021-12-13 |
|
|
| 721 |
Recent Studies Suggest That Dop Agonist May Have Biased Ligands |
2021-12-10 |
|
|
| 722 |
Facilitating Effects on Fear Extinction Learning Observed With Dop Agonists |
2021-12-10 |
|
|
| 723 |
Current Status and Issues in the Development of Therapeutic Drugs for Ptsd |
2021-12-10 |
|
|
| 724 |
Stem Cell Overview |
2021-12-10 |
|
|
| 725 |
Fault Seal Assessment |
2021-12-09 |
|
|
| 726 |
Geophysical Interpretation |
2021-12-09 |
|
|
| 727 |
Risk Factors for Patients with Hematologic Malignancies |
2021-12-08 |
|
|
| 728 |
Fish Preservation Methods |
2021-12-02 |
|
|
| 729 |
Antibiotic Resistance |
2021-12-02 |
|
|
| 730 |
Foodborne Diseases |
2021-12-02 |
|
|
| 731 |
Microflora of Fish and Fish Environments |
2021-12-02 |
|
|
| 732 |
Bacterial Fish Contamination |
2021-12-02 |
|
|
| 733 |
Fish Contamination |
2021-12-02 |
|
|
| 734 |
Surrogacy |
2021-11-26 |
|
|
| 735 |
Cryopreservation |
2021-11-26 |
|
|
| 736 |
Conflicts of Insterest |
2021-11-25 |
|
|
| 737 |
Author Information |
2021-11-25 |
|
|
| 738 |
Animal Ethical Approval |
2021-11-25 |
|
|
| 739 |
Ethics Declarations |
2021-11-25 |
|
|
| 740 |
Availability of Data any Material |
2021-11-25 |
|
|
| 741 |
Determination of Floating Behavior |
2021-11-20 |
|
|
| 742 |
Sensory Test |
2021-11-20 |
|
|
| 743 |
Particle Size And Morphology Evaluation |
2021-11-20 |
|
|
| 744 |
Application to A Clinical Pharmacokinetic Study |
2021-11-20 |
|
|
| 745 |
Arrangement of Plant Extricates |
2021-11-20 |
|
|
| 746 |
Editotrial Note |
2021-11-12 |
|
|
| 747 |
Test for Leprosy |
2021-11-11 |
|
|
| 748 |
Causes and Treatment |
2021-11-11 |
|
|
| 749 |
Symptoms and Treatment |
2021-11-11 |
|
|
| 750 |
Types and Causes of Skin Cancer |
2021-11-11 |
|
|
| 751 |
Steps For Mipo Technique |
2021-11-10 |
|
|
| 752 |
Surgical Steps For Supracutaneous Plating |
2021-11-10 |
|
|
| 753 |
Sine Gordon Expansion Method |
2021-11-09 |
|
|
| 754 |
Characteristics That Were Selected For Experiment |
2021-11-05 |
|
|
| 755 |
Selection of the Experimental Plants |
2021-11-05 |
|
|
| 756 |
Convergence Conditions |
2021-11-03 |
|
|
| 757 |
System of Linear Equations |
2021-11-03 |
|
|
| 758 |
Direct and Interactive Methods for Solving a System of Linear Equations |
2021-11-03 |
|
|
| 759 |
Social media a fresh platform for futuristic surgical learning: Overview |
2021-10-27 |
|
|
| 760 |
Is minimal invasive technique in cardiac surgery preferable over traditional technique? |
2021-10-27 |
|
|
| 761 |
Mental willingness, PTSD and surgical outcomes correlation: Overview |
2021-10-27 |
|
|
| 762 |
Pre-surgical opioid prescriptions leading to chronic opioid abuse |
2021-10-27 |
|
|
| 763 |
Women underrepresentation in surgical field: Overview |
2021-10-27 |
|
|
| 764 |
Accessibility of the Healthcare |
2021-10-26 |
|
|
| 765 |
Animal-Related Diseases |
2021-10-26 |
|
|
| 766 |
Vector-Borne Diseases |
2021-10-26 |
|
|
| 767 |
Sexually Transmitted Infections (STIs) |
2021-10-26 |
|
|
| 768 |
Hepatitis A |
2021-10-26 |
|
|
| 769 |
Infectious Disease Risks for Qatar 2022 Attendees and Disease-Specific Prevention Recommendations |
2021-10-26 |
|
|
| 770 |
Pretravel Health Care and vaccination |
2021-10-26 |
|
|
| 771 |
Sagittal plane - Non-structural misalignments of body posture |
2021-10-26 |
|
|
| 772 |
Acute Traumatic Coagulopathy |
2021-10-26 |
|
|
| 773 |
Chondroradionecrosis of the Larynx |
2021-10-26 |
|
|
| 774 |
Editorial Note on Hip arthroplasty |
2021-10-26 |
|
|
| 775 |
History of Organ Transplantation |
2021-10-26 |
|
|
| 776 |
Development of microfluidic devices for fertility |
2021-10-21 |
|
|
| 777 |
Methods of Echocardiogram |
2021-10-19 |
|
|
| 778 |
Deformities of Echocardiogram |
2021-10-19 |
|
|
| 779 |
Pulmonary Circulation |
2021-10-19 |
|
|
| 780 |
Survey And Feedback |
2021-10-19 |
|
|
| 781 |
Memberships And Reprints |
2021-10-19 |
|
|
| 782 |
Advertisement Platform |
2021-10-19 |
|
|
| 783 |
Submission Process |
2021-10-19 |
|
|
| 784 |
Article Types |
2021-10-19 |
|
|
| 785 |
SLI Disorder with Multiple Underlying Deficits |
2021-10-18 |
|
|
| 786 |
Clinical suggestions |
2021-10-18 |
|
|
| 787 |
Genetic influences on different aspects of Language Impairment |
2021-10-18 |
|
|
| 788 |
Acute Bacterial Meningitis |
2021-10-18 |
|
|
| 789 |
Extra-axial empyema |
2021-10-18 |
|
|
| 790 |
Neuropsychological interventions |
2021-10-18 |
|
|
| 791 |
Etiology and pathophysiology |
2021-10-18 |
|
|
| 792 |
Ultrasound-guided central line insertion |
2021-10-18 |
|
|
| 793 |
Ultrasound and cystic hygroma |
2021-10-18 |
|
|
| 794 |
Ultrasonography techniques |
2021-10-18 |
|
|
| 795 |
Dissociative Amnesia Treated |
2021-10-18 |
|
|
| 796 |
Moral misery of NICU staff |
2021-10-18 |
|
|
| 797 |
Dissociative Amnesia Diagnosed |
2021-10-18 |
|
|
| 798 |
Effect of a pandemic on the NICU |
2021-10-18 |
|
|
| 799 |
Contemplations on life-and-demise choices during a pandemic |
2021-10-18 |
|
|
| 800 |
Ordinary life-and-passing dynamic in the NICU |
2021-10-18 |
|
|
| 801 |
Early learning and childcare practitioner |
2021-10-18 |
|
|
| 802 |
Theories of child development |
2021-10-18 |
|
|
| 803 |
Child development |
2021-10-18 |
|
|
| 804 |
Adult Changes in Thought (ACT) |
2021-10-18 |
|
|
| 805 |
Challenges of activation of adult NSCs |
2021-10-18 |
|
|
| 806 |
Age-dependent decrease in neural stem cells and adult neurogenesis |
2021-10-18 |
|
|
| 807 |
Origin of adult NSCs |
2021-10-18 |
|
|
| 808 |
Systemic Circulatory System |
2021-10-14 |
|
|
| 809 |
Short Commentary |
2021-10-08 |
|
|
| 810 |
Impacts of atmospheric black carbon on climate |
2021-10-08 |
|
|
| 811 |
A remedy to global warming and the energy crisis |
2021-10-08 |
|
|
| 812 |
Environmentally sustainable chemistry |
2021-10-08 |
|
|
| 813 |
Vehicle pollutes the atmosphere and poses health hazards |
2021-10-08 |
|
|
| 814 |
Radioactive pollution in environment |
2021-10-08 |
|
|
| 815 |
AIDS |
2021-09-30 |
|
|
| 816 |
The Primordial Cells and Metabolism |
2021-09-30 |
|
|
| 817 |
Acne and the Menstrual Cycle |
2021-09-30 |
|
|
| 818 |
Types of Cancer |
2021-09-30 |
|
|
| 819 |
Applications |
2021-09-29 |
|
|
| 820 |
short |
2021-09-27 |
|
|
| 821 |
LETTER |
2021-09-14 |
|
|
| 822 |
Viewpoint |
2021-09-09 |
|
|
| 823 |
Diagnosis Observations |
2021-09-07 |
|
|
| 824 |
Classification of Tooth Fractures by Talim and Gohil |
2021-09-07 |
|
|
| 825 |
Types of Furcation Fractures |
2021-09-07 |
|
|
| 826 |
Perfadex Solution |
2021-09-06 |
|
|
| 827 |
IGL-1 Solution |
2021-09-06 |
|
|
| 828 |
Kyoto University Preservation Solution |
2021-09-06 |
|
|
| 829 |
Celsior Solution |
2021-09-06 |
|
|
| 830 |
Bretschneider's (Custodiol) Solution |
2021-09-06 |
|
|
| 831 |
Citrate Solutions (Marshall/Ross) |
2021-09-06 |
|
|
| 832 |
University of Wisconsin Solution (UW) |
2021-09-06 |
|
|
| 833 |
Collins Solution |
2021-09-06 |
|
|
| 834 |
Preservation Solutions |
2021-09-06 |
|
|
| 835 |
Author's Contribution |
2021-09-06 |
|
|
| 836 |
Subject |
2021-09-03 |
|
|
| 837 |
Microorganisms Utilized to Change Over the Lactose Sugars into Lactic Corrosive |
2021-09-01 |
|
|
| 838 |
Clinical and Vaccine Immunology Improves Comprehension of Resistant |
2021-09-01 |
|
|
| 839 |
Recombinant DNA Innovation Utilizes Microorganisms |
2021-09-01 |
|
|
| 840 |
Antigens Regularly Lead to a Resistant Reaction of Tumor |
2021-09-01 |
|
|
| 841 |
Pathogenic Organisms Challenge the Insusceptible Framework |
2021-09-01 |
|
|
| 842 |
The significant site of CSF development is the choroid plexus |
2021-09-01 |
|
|
| 843 |
Hypospadias Influences Around 1 In Each 500 Infant Boys |
2021-08-31 |
|
|
| 844 |
Embryonic Undifferentiated Organisms Can Separate Into More Cell |
2021-08-31 |
|
|
| 845 |
Pre-Birth Conclusion Implies Determination Before Birth |
2021-08-31 |
|
|
| 846 |
Single Cell Cluster Comparative Genomic Hybridisation Exhibit |
2021-08-31 |
|
|
| 847 |
Ultrastructure Investigations of Creating Muscle By Transmission Electron Microscopy |
2021-08-31 |
|
|
| 848 |
Enzyme Inhibition |
2021-08-30 |
|
|
| 849 |
Anticancer |
2021-08-30 |
|
|
| 850 |
Antioxidant |
2021-08-30 |
|
|
| 851 |
Anti-Inflammatory |
2021-08-30 |
|
|
| 852 |
Applications of Flavinoids |
2021-08-30 |
|
|
| 853 |
Pathologic exam of a biopsy |
2021-08-30 |
|
|
| 854 |
Anti-Cancer drugs as part of chemotherapy regimen |
2021-08-30 |
|
|
| 855 |
Oncogene can also an cellular to secrete boom factors |
2021-08-30 |
|
|
| 856 |
Carcinoma is extra dependent on the size of tumor |
2021-08-30 |
|
|
| 857 |
Possible signs and symptoms encompass lump |
2021-08-30 |
|
|
| 858 |
Symptoms of Psoriasis |
2021-08-27 |
|
|
| 859 |
Prescribing Pattern |
2021-08-27 |
|
|
| 860 |
Source(S) of Support/Funding |
2021-08-25 |
|
|
| 861 |
From or to Icu |
2021-08-25 |
|
|
| 862 |
Postpone Nonessential Surgeries |
2021-08-25 |
|
|
| 863 |
Personal Protective Equipment |
2021-08-25 |
|
|
| 864 |
Role of Anesthesiologist |
2021-08-25 |
|
|
| 865 |
In Closing |
2021-08-24 |
|
|
| 866 |
The Relation between the Diaphragm, the Heart and the Kidneys |
2021-08-24 |
|
|
| 867 |
The Diaphragm’s Influence on the Release of Atrial Natriuretic Peptide |
2021-08-24 |
|
|
| 868 |
The Stimulus for the Release of Atrial Natriuretic Peptide |
2021-08-24 |
|
|
| 869 |
The Absence of Atrial Natriuretic Peptide and the Kidneys |
2021-08-24 |
|
|
| 870 |
The Positive Effect that Atrial Natriuretic Peptide has on the Kidneys |
2021-08-24 |
|
|
| 871 |
Atrial Natriuretic Peptide |
2021-08-24 |
|
|
| 872 |
Ethics Compliance |
2021-08-24 |
|
|
| 873 |
Endpoints |
2021-08-24 |
|
|
| 874 |
Alcohol Consumption |
2021-08-20 |
|
|
| 875 |
Image Analysis |
2021-08-17 |
|
|
| 876 |
Methods and Result Of Dissection |
2021-08-16 |
|
|
| 877 |
Method |
2021-08-16 |
|
|
| 878 |
Emotional Well-Being of HIV/AIDS Patients |
2021-08-16 |
|
|
| 879 |
Editorial note on Profoundly Active Anti-Retroviral Therapy |
2021-08-16 |
|
|
| 880 |
HIV/AIDS to HIV Cancer |
2021-08-16 |
|
|
| 881 |
Indirect Way |
2021-08-13 |
|
|
| 882 |
Direct Way |
2021-08-13 |
|
|
| 883 |
Classification of Lumbar Spinal Stenosis |
2021-08-13 |
|
|
| 884 |
Method and Materials |
2021-08-13 |
|
|
| 885 |
Technique |
2021-08-12 |
|
|
| 886 |
Association of Bisphenol-A with Neuro Developmental Disorders |
2021-08-12 |
|
|
| 887 |
Effective Measurement of Bisphenol-A |
2021-08-12 |
|
|
| 888 |
Bisphenol-A |
2021-08-12 |
|
|
| 889 |
Case Representation |
2021-08-12 |
|
|
| 890 |
Goals and Objectives |
2021-08-10 |
|
|
| 891 |
Aims and Scope |
2021-08-10 |
|
|
| 892 |
Innovation |
2021-08-10 |
|
|
| 893 |
Current opinion |
2021-08-09 |
|
|
| 894 |
Emerging Role of Robotics in Skull Base Surgery |
2021-08-09 |
|
|
| 895 |
Advantages and Drawbacks of Surgery in Treatment of Gastro Esophageal Reflux: An Overview |
2021-08-09 |
|
|
| 896 |
Evolution of Micro vascular Surgery: An Overview |
2021-08-09 |
|
|
| 897 |
Molecular Fluorescence Imaging to Assist Surgery |
2021-08-09 |
|
|
| 898 |
Hydroxyurea |
2021-08-07 |
|
|
| 899 |
Chronic Complications |
2021-08-07 |
|
|
| 900 |
Acute Complications |
2021-08-07 |
|
|
| 901 |
Health Maintenance |
2021-08-07 |
|
|
| 902 |
Opinion Article |
2021-08-07 |
|
|
| 903 |
Editorial Note for Surgery: Case Reports Journal |
2021-08-07 |
|
|
| 904 |
EFFECTS ON FERTILITY |
2021-08-06 |
|
|
| 905 |
Symptoms |
2021-08-06 |
|
|
| 906 |
Causes |
2021-08-06 |
|
|
| 907 |
Mini Review |
2021-08-06 |
|
|
| 908 |
Brief Report |
2021-07-31 |
|
|
| 909 |
Prime Focus |
2021-07-29 |
|
|
| 910 |
Current Regulatory Requirements for Absence of Mycoplasma in Vaccines for Human Use |
2021-07-27 |
|
|
| 911 |
Pharmacopeial Specifications for Testing of Mycoplasma |
2021-07-27 |
|
|
| 912 |
Mycoplasma Testing Methods |
2021-07-27 |
|
|
| 913 |
Ocular Manifestations |
2021-07-27 |
|
|
| 914 |
Assurance of MIC |
2021-07-27 |
|
|
| 915 |
Editorial Note on Multidrug Resistant |
2021-07-27 |
|
|
| 916 |
Funding Disclosure |
2021-07-20 |
|
|
| 917 |
Limitations and Problems |
2021-07-20 |
|
|
| 918 |
Pain and Altered Mental Status |
2021-07-20 |
|
|
| 919 |
Therapy and Prevention |
2021-07-19 |
|
|
| 920 |
Diagnostic Challenge |
2021-07-19 |
|
|
| 921 |
Disorder of Social Behaviour |
2021-07-19 |
|
|
| 922 |
Symptoms Overlap ADHD and SUD |
2021-07-19 |
|
|
| 923 |
Neurological Complications |
2021-07-19 |
|
|
| 924 |
Linked Alterations in Gray and White Matter Morphology in Adults Withhigh-Functioning Autism Spectrum Disorder |
2021-07-14 |
|
|
| 925 |
ANNOUNCEMENT: CALL FOR PAPER |
2021-07-14 |
|
|
| 926 |
Ethics of Human and Animal Experiments |
2021-06-30 |
|
|
| 927 |
Policy Issues |
2021-06-30 |
|
|
| 928 |
Observation and Results |
2021-06-30 |
|
|
| 929 |
Data Collection |
2021-06-15 |
|
|
| 930 |
Toxicity |
2021-06-14 |
|
|
| 931 |
Pharmacogenetic Effect |
2021-06-14 |
|
|
| 932 |
Review on Acute Myeloid Leukemia |
2021-06-09 |
|
|
| 933 |
Thrombophlebitis |
2021-06-03 |
|
|
| 934 |
Pathophysiology of Varicose Veins |
2021-06-03 |
|
|
| 935 |
INTRODUCTION |
2021-06-03 |
|
|
| 936 |
Case-2 |
2021-06-03 |
|
|
| 937 |
Case-1 |
2021-06-03 |
|
|
| 938 |
Eligibility Criteria for Young Scientist Awards: Probiotics Asia Pacific 2021 |
2021-06-03 |
|
|
| 939 |
About Conference Series |
2021-06-03 |
|
|
| 940 |
Future of DNA analysis |
2021-05-16 |
|
|
| 941 |
Clinical application of DNA microarray |
2021-05-16 |
|
|
| 942 |
Applications of machine learning in multiple fields |
2021-05-16 |
|
|
| 943 |
How do we estimate Visualization Techniques? |
2021-05-16 |
|
|
| 944 |
Materilas and Methods |
2021-05-14 |
|
|
| 945 |
Analytical Techniques |
2021-05-12 |
|
|
| 946 |
Advances in Analytical Toxicology |
2021-05-12 |
|
|
| 947 |
Factors Influencing Toxicology |
2021-05-12 |
|
|
| 948 |
About the Study |
2021-05-04 |
|
|
| 949 |
The Emerging Spectrum of Covid-19 Neurology |
2021-05-03 |
|
|
| 950 |
Neuropathological Features of Covid-19 |
2021-05-03 |
|
|
| 951 |
Covid-19 and Acute Ischemic Stroke |
2021-05-03 |
|
|
| 952 |
Age and Stroke |
2021-05-03 |
|
|
| 953 |
Microbleeds |
2021-05-03 |
|
|
| 954 |
Showcasing and Patient Hopes |
2021-04-27 |
|
|
| 955 |
Vital Things for Patients |
2021-04-27 |
|
|
| 956 |
Declaration Statements |
2021-04-27 |
|
|
| 957 |
Conclusions and Recommendations |
2021-04-27 |
|
|
| 958 |
Data Collection and Analysis |
2021-04-26 |
|
|
| 959 |
Objective of the Study |
2021-04-26 |
|
|
| 960 |
Blood Sampling Methods |
2021-04-26 |
|
|
| 961 |
Methodology and Problem |
2021-04-26 |
|
|
| 962 |
Consent for Publishing |
2021-04-22 |
|
|
| 963 |
Multidisciplinary Treatment Planning and Execution |
2021-04-21 |
|
|
| 964 |
Multi-environment evaluation and genotype x environment interaction analysis of sorghum [sorghum bicolor (l.) Moench] genotypes in highland areas of ethiopia |
2021-04-19 |
|
|
| 965 |
Abbrevations |
2021-04-16 |
|
|
| 966 |
Bioleaching is Influenced by A Number of Factors |
2021-04-15 |
|
|
| 967 |
Prevention and Control |
2021-04-15 |
|
|
| 968 |
Editorials |
2021-04-15 |
|
|
| 969 |
Classification of Hydrochemical Facies |
2021-04-15 |
|
|
| 970 |
Evaluation of Irrigation Water Indices |
2021-04-15 |
|
|
| 971 |
Evaluation of Drinking Water Quality |
2021-04-15 |
|
|
| 972 |
Hydrogeochemical Analysis Results and Interpretation |
2021-04-15 |
|
|
| 973 |
Depth to Water and Aquifer Thickness |
2021-04-15 |
|
|
| 974 |
Correlation of Geo-Electric Log and Lithology Log |
2021-04-15 |
|
|
| 975 |
Hydrochemical Investigation |
2021-04-15 |
|
|
| 976 |
Vertical Electrical Sounding Survey (VES) |
2021-04-15 |
|
|
| 977 |
Geology and Hydrogeology |
2021-04-15 |
|
|
| 978 |
Description of the Study Area |
2021-04-15 |
|
|
| 979 |
Selection of an Antidepressant Medication |
2021-04-14 |
|
|
| 980 |
Drug Use |
2021-04-14 |
|
|
| 981 |
Drug Screening |
2021-04-14 |
|
|
| 982 |
Stages of Drug Development |
2021-04-14 |
|
|
| 983 |
Treatment of Infertility |
2021-04-07 |
|
|
| 984 |
Female Fertility Triggers |
2021-04-07 |
|
|
| 985 |
Male Infertility Causes |
2021-04-07 |
|
|
| 986 |
Progenesis |
2021-04-07 |
|
|
| 987 |
Clinical Characteristics |
2021-04-07 |
|
|
| 988 |
Is it Possible to Avoid Genetic Abnormalities? |
2021-04-07 |
|
|
| 989 |
Fetal Genetic Disorders |
2021-04-07 |
|
|
| 990 |
Different Types of Disorders Developed During Pregnancy |
2021-04-07 |
|
|
| 991 |
How to Avoid Endocrine Disruptors? |
2021-04-07 |
|
|
| 992 |
Effects of Endocrine Disruptors |
2021-04-07 |
|
|
| 993 |
Different Sources for Endocrine Disruptors |
2021-04-07 |
|
|
| 994 |
Various types of Endocrine Disruptors |
2021-04-07 |
|
|
| 995 |
Conclusion Remarks and Future Predictions |
2021-04-07 |
|
|
| 996 |
Main Results |
2021-04-07 |
|
|
| 997 |
Methodology of Analysis |
2021-04-07 |
|
|
| 998 |
Approximation of Functions |
2021-04-07 |
|
|
| 999 |
Function Interpolation |
2021-04-07 |
|
|
| 1000 |
Basic Terms |
2021-04-07 |
|
|
| 1001 |
Eccenticity |
2021-04-07 |
|
|
| 1002 |
Prevention to Control Soil Erosion |
2021-04-06 |
|
|
| 1003 |
Operative Methods |
2021-04-02 |
|
|
| 1004 |
Abstact |
2021-04-02 |
|
|
| 1005 |
What is the Ideal Eccentric Compression System? |
2021-03-29 |
|
|
| 1006 |
Which Compression, Digressive or Eccentric Compression? |
2021-03-29 |
|
|
| 1007 |
Why are we divided on the Utility of Compression after Endo Venous Treatments? |
2021-03-29 |
|
|
| 1008 |
Myocardial Infarction and its causes |
2021-03-26 |
|
|
| 1009 |
Myocardial Infraction and its causes |
2021-03-25 |
|
|
| 1010 |
Risks |
2021-03-24 |
|
|
| 1011 |
Exercises |
2021-03-24 |
|
|
| 1012 |
Recovery |
2021-03-24 |
|
|
| 1013 |
Tools used in bioinformatics |
2021-03-15 |
|
|
| 1014 |
Presentation at meetings |
2021-03-12 |
|
|
| 1015 |
Report of a Case |
2021-03-12 |
|
|
| 1016 |
Conflicts of Interest / Competing Interests |
2021-03-12 |
|
|
| 1017 |
Editorial Highlights for Journal of Nursing Research and Practice |
2021-03-03 |
|
|
| 1018 |
Retrospective Study |
2021-02-04 |
|
|
| 1019 |
Societal Perspective |
2021-02-03 |
|
|
| 1020 |
Economic Recovery and Reopening: A Lego Modular Approach to the Unknown |
2021-02-03 |
|
|
| 1021 |
Multiplex Testing: a Must Have for Fall and Controlling a Second Wave |
2021-02-03 |
|
|
| 1022 |
The Role of the Public Health Response |
2021-02-03 |
|
|
| 1023 |
It Takes Two to Tango: How South Korea Refused to Dance with Covid-19 |
2021-02-03 |
|
|
| 1024 |
How Deep is the Economic Valley |
2021-02-03 |
|
|
| 1025 |
Further Improvements in Policies |
2021-01-29 |
|
|
| 1026 |
Impacts of the Policy on the Health of the Children |
2021-01-29 |
|
|
| 1027 |
Sugar Tax Policy for Children Health |
2021-01-29 |
|
|
| 1028 |
Policies to Cure Children Health |
2021-01-29 |
|
|
| 1029 |
Health Related Issues for Children |
2021-01-29 |
|
|
| 1030 |
Application of Nmc Code |
2021-01-29 |
|
|
| 1031 |
Conflicts of Interest and Informed Consent |
2021-01-28 |
|
|
| 1032 |
Case Report (3) |
2021-01-28 |
|
|
| 1033 |
Case Report (2) |
2021-01-28 |
|
|
| 1034 |
Relevance of the Study |
2021-01-22 |
|
|
| 1035 |
Response From WHO |
2021-01-22 |
|
|
| 1036 |
Impact |
2021-01-22 |
|
|
| 1037 |
Discussion and Management |
2021-01-12 |
|
|
| 1038 |
Clinical Manifestations |
2021-01-12 |
|
|
| 1039 |
Method of saliva collection |
2021-01-12 |
|
|
| 1040 |
Literature Search |
2021-01-11 |
|
|
| 1041 |
Vein Glue Allergy |
2020-12-28 |
|
|
| 1042 |
Exercise, Nutrition and Alcohol Reduction |
2020-12-24 |
|
|
| 1043 |
Practical Guidelines Developed by Practitioners to Improve the Health and Well-Being of Both Individuals |
2020-12-24 |
|
|
| 1044 |
Principles of Health and Fitness and the Issues and Agendas Concerning a Healthy Lifestyle |
2020-12-24 |
|
|
| 1045 |
Patient Assessment |
2020-12-18 |
|
|
| 1046 |
Experimental Results |
2020-12-16 |
|
|
| 1047 |
Limitations and Future Research |
2020-12-16 |
|
|
| 1048 |
Ophthalmology |
2020-12-15 |
|
|
| 1049 |
Occurrence of Glaucoma |
2020-12-15 |
|
|
| 1050 |
Testing of Drug |
2020-12-03 |
|
|
| 1051 |
Monitoring the Drug |
2020-12-03 |
|
|
| 1052 |
Significance of TDM |
2020-12-03 |
|
|
| 1053 |
Process of Drug Development |
2020-12-03 |
|
|
| 1054 |
Intuition of Pharmacovigilance |
2020-12-03 |
|
|
| 1055 |
Circulatory strain |
2020-12-03 |
|
|
| 1056 |
Sickle Cell Anemia |
2020-12-03 |
|
|
| 1057 |
Erectile dysfunction |
2020-12-03 |
|
|
| 1058 |
Prostate carcinoma |
2020-12-03 |
|
|
| 1059 |
Uterine Fibroids ndometriosis |
2020-12-03 |
|
|
| 1060 |
Polycystic Ovary Syndrome |
2020-12-03 |
|
|
| 1061 |
Aims |
2020-12-02 |
|
|
| 1062 |
Women Health Nursing |
2020-12-02 |
|
|
| 1063 |
Surgery Nursing |
2020-12-02 |
|
|
| 1064 |
Public Health Nursing |
2020-12-02 |
|
|
| 1065 |
Pediatric Nursing |
2020-12-02 |
|
|
| 1066 |
Oncology and Cancer Nursing |
2020-12-02 |
|
|
| 1067 |
Editorial on Nano Based Benefits in Agriculture |
2020-11-21 |
|
|
| 1068 |
Case Represntation |
2020-11-13 |
|
|
| 1069 |
Research Study |
2020-10-21 |
|
|
| 1070 |
Eligibility |
2020-10-16 |
|
|
| 1071 |
[Cognitive Psychotherapy2020] Young Scientist Awards |
2020-10-16 |
|
|
| 1072 |
Subject Advantages: |
2020-10-16 |
|
|
| 1073 |
Why should attend? |
2020-10-16 |
|
|
| 1074 |
Declaration of Competing Interest |
2020-09-09 |
|
|
| 1075 |
Recommendations and Sustainability Plan |
2020-09-09 |
|
|
| 1076 |
Lessons Learnt |
2020-09-09 |
|
|
| 1077 |
Methodology Overview |
2020-09-09 |
|
|
| 1078 |
Project Goals |
2020-09-09 |
|
|
| 1079 |
Case Series |
2020-09-07 |
|
|
| 1080 |
Contraception |
2020-08-31 |
|
|
| 1081 |
Reproductive Medicine |
2020-08-31 |
|
|
| 1082 |
Iron Deficiency Anemia |
2020-08-31 |
|
|
| 1083 |
Haemoglobin |
2020-08-31 |
|
|
| 1084 |
Haematology |
2020-08-31 |
|
|
| 1085 |
Signs and side effects |
2020-08-31 |
|
|
| 1086 |
Blood Pressure |
2020-08-31 |
|
|
| 1087 |
Retraction Note |
2020-08-29 |
|
|
| 1088 |
Clinical Case |
2020-08-21 |
|
|
| 1089 |
Patient and Methods |
2020-08-21 |
|
|
| 1090 |
Disclosure and Conflict of Interest |
2020-08-20 |
|
|
| 1091 |
Discussion and Review of Literature |
2020-08-20 |
|
|
| 1092 |
Pathomechanics |
2020-08-20 |
|
|
| 1093 |
Lever Sign Test |
2020-08-20 |
|
|
| 1094 |
Research Interest |
2020-08-19 |
|
|
| 1095 |
Social Media |
2020-08-19 |
|
|
| 1096 |
Insight of the Journal |
2020-08-19 |
|
|
| 1097 |
Journal Topics |
2020-08-19 |
|
|
| 1098 |
Role of Pharmacology of Covid 19 |
2020-08-19 |
|
|
| 1099 |
TO-NSTEMI |
2020-08-14 |
|
|
| 1100 |
Further Research |
2020-08-14 |
|
|
| 1101 |
Transport of Carbon dioxide to lungs |
2020-08-08 |
|
|
| 1102 |
Structure of haemoglobin |
2020-08-08 |
|
|
| 1103 |
Conclusion and Future Work |
2020-08-08 |
|
|
| 1104 |
Results and Validation |
2020-08-08 |
|
|
| 1105 |
Data Collection and Preprocessing |
2020-08-08 |
|
|
| 1106 |
Blood Cells |
2020-08-08 |
|
|
| 1107 |
Coagulation |
2020-08-08 |
|
|
| 1108 |
Whole Blood Cells |
2020-08-08 |
|
|
| 1109 |
Function of Blood |
2020-08-08 |
|
|
| 1110 |
Comparison and Discussion |
2020-08-08 |
|
|
| 1111 |
System Architecture |
2020-08-08 |
|
|
| 1112 |
Ambient Sensors and Wearables |
2020-08-08 |
|
|
| 1113 |
Expected Impact |
2020-08-08 |
|
|
| 1114 |
Results and Discussions |
2020-08-08 |
|
|
| 1115 |
Study Intervention |
2020-08-07 |
|
|
| 1116 |
Note |
2020-08-07 |
|
|
| 1117 |
Conclusion and Significance |
2020-08-07 |
|
|
| 1118 |
Conflict of Interest |
2020-08-06 |
|
|
| 1119 |
Compliance with Ethical Standards |
2020-08-06 |
|
|
| 1120 |
Ethical Responsibilities |
2020-08-05 |
|
|
| 1121 |
Level of Evidence |
2020-08-05 |
|
|
| 1122 |
Plastic Surgery Engagement And Future Directions |
2020-07-29 |
|
|
| 1123 |
Reconstructive Surgery Options |
2020-07-29 |
|
|
| 1124 |
Historical Management of FGM |
2020-07-29 |
|
|
| 1125 |
Our Discussion: Oxygen Therapy – Vascular and Further Indications |
2020-07-23 |
|
|
| 1126 |
Casuistic View |
2020-07-23 |
|
|
| 1127 |
Therapeutic View: Oxygen Therapy for Varicose Veins - Our Therapeutic Consequences |
2020-07-23 |
|
|
| 1128 |
Therapeutical View: Oxygen Therapy for Varicose Veins - What Can We Do? |
2020-07-23 |
|
|
| 1129 |
And Here Lies the Causative Pathological Connection to Leg Varices |
2020-07-23 |
|
|
| 1130 |
Pathophysiological View: Oxygen Therapy for Varicose Veins - The Pathology of Microcirculation in the Leg Capillaries |
2020-07-23 |
|
|
| 1131 |
Oxygen Therapy for Varicose Veins: Lack of Oxygen, Lack of Cell Energy |
2020-07-23 |
|
|
| 1132 |
Discussion-Quoted From the Guideline for Compression Therapy |
2020-07-23 |
|
|
| 1133 |
Results-Our First Experiences with Postoperative Massage Therapy |
2020-07-23 |
|
|
| 1134 |
Pathophysiological Considerations-Ipc after Varicose Vein Therapy |
2020-07-23 |
|
|
| 1135 |
Saphenion: Compression Massage after Vein Glue/Microfoam |
2020-07-23 |
|
|
| 1136 |
History-Massage of the Leg after Venaseal or Sealing Foam Therapy |
2020-07-23 |
|
|
| 1137 |
Thanks and Acknowledgments to Important Reviewers and Editors for Their Contribution |
2020-07-23 |
|
|
| 1138 |
Using Social Media/Digital Marketing to Showcase Articles Published in Your Journal |
2020-07-23 |
|
|
| 1139 |
Objectives of 2021 |
2020-07-23 |
|
|
| 1140 |
Highlights of 2019 |
2020-07-23 |
|
|
| 1141 |
About The Journal |
2020-07-23 |
|
|
| 1142 |
Editorial Content |
2020-07-22 |
|
|
| 1143 |
Editor’s Note |
2020-07-20 |
|
|
| 1144 |
Declaration of Patient Consent |
2020-07-10 |
|
|
| 1145 |
Interviews |
2020-07-09 |
|
|
| 1146 |
System Design |
2020-07-09 |
|
|
| 1147 |
Experiments |
2020-07-09 |
|
|
| 1148 |
Google Analytics |
2020-07-06 |
|
|
| 1149 |
Scope of the journal |
2020-07-06 |
|
|
| 1150 |
Research and Reviews |
2020-07-06 |
|
|
| 1151 |
Authors’ Note |
2020-07-03 |
|
|
| 1152 |
Authors’ Note |
2020-07-03 |
|
|
| 1153 |
Biography |
2020-07-01 |
|
|
| 1154 |
Treatment Options |
2020-06-02 |
|
|
| 1155 |
Editorial Note |
2020-06-02 |
|
|
| 1156 |
Rational of the Study |
2020-05-08 |
|
|
| 1157 |
Perception of Mental Health among Adolescents and Self Concept |
2020-05-08 |
|
|
| 1158 |
Anxiety and Depression among Adolescent |
2020-05-08 |
|
|
| 1159 |
Mental Health Problems among Adolescents |
2020-05-08 |
|
|
| 1160 |
Mechanical Postconditioning |
2020-03-19 |
|
|
| 1161 |
Thrombus Aspiration |
2020-03-19 |
|
|
| 1162 |
Pharmacological Treatment |
2020-03-19 |
|
|
| 1163 |
Risk Factors and Outcomes of No-Reflow |
2020-03-19 |
|
|
| 1164 |
Thematic Analysis |
2020-03-13 |
|
|
| 1165 |
Declarations of Interest |
2020-03-13 |
|
|
| 1166 |
Implications for Nursing Practice |
2020-03-03 |
|
|
| 1167 |
Effects of Intrascrotal Pressure on Testis |
2020-03-02 |
|
|
| 1168 |
Method of Data Collection and Analysis |
2020-03-02 |
|
|
| 1169 |
Global Market Value |
2020-02-28 |
|
|
| 1170 |
Targeted Audience |
2020-02-28 |
|
|
| 1171 |
Research Methods |
2020-02-17 |
|
|
| 1172 |
Funding Support |
2020-02-17 |
|
|
| 1173 |
Financial Disclosure |
2020-02-17 |
|
|
| 1174 |
Source of Founding |
2020-02-17 |
|
|
| 1175 |
Knee Function Postoperative Results |
2020-02-17 |
|
|
| 1176 |
Clinical Outcomes |
2020-02-17 |
|
|
| 1177 |
Awards 2020 |
2020-02-11 |
|
|
| 1178 |
2020 Conference Announcement |
2020-02-11 |
|
|
| 1179 |
Consent for Publication |
2020-02-10 |
|
|
| 1180 |
Best Organising Committee Member of Neuro Meet 2020 |
2020-02-10 |
|
|
| 1181 |
The 8th International Conference on Neuroscience and Neurological Disorders 2020 |
2020-02-10 |
|
|
| 1182 |
7th Annual meeting on Neurosurgery and Neurological surgeons |
2020-02-10 |
|
|
| 1183 |
Young Research Forum Announcement |
2020-02-05 |
|
|
| 1184 |
Literature Review – A Case Scenario |
2020-01-27 |
|
|
| 1185 |
Conference Opportunities: |
2020-01-24 |
|
|
| 1186 |
What’s New this year? |
2020-01-24 |
|
|
| 1187 |
Announcement |
2020-01-24 |
|
|
| 1188 |
Understudy Ambassador Award |
2020-01-24 |
|
|
| 1189 |
Youthful Research Award |
2020-01-24 |
|
|
| 1190 |
Professional Level (The Research commitment Award) |
2020-01-24 |
|
|
| 1191 |
Immunology Drug Market Segmentation |
2020-01-22 |
|
|
| 1192 |
Immunology Market Research will allow you to |
2020-01-22 |
|
|
| 1193 |
Infectious Diseases Diagnostics Market |
2020-01-22 |
|
|
| 1194 |
Tourist Attraction |
2020-01-22 |
|
|
| 1195 |
Criteria for The Best Poster Presentation Award |
2020-01-22 |
|
|
| 1196 |
The Best Poster Presentation Award |
2020-01-22 |
|
|
| 1197 |
Session’s Best Presentation Awards |
2020-01-22 |
|
|
| 1198 |
Criteria for the Best Student Presentation Award |
2020-01-22 |
|
|
| 1199 |
The Best Student Presentation Award |
2020-01-22 |
|
|
| 1200 |
Best Paper Award |
2020-01-22 |
|
|
| 1201 |
Best Poster Award Nursing 2020 |
2020-01-22 |
|
|
| 1202 |
Best Organising Committee Member Nursing Care 2020 |
2020-01-22 |
|
|
| 1203 |
Best Keynote Speaker Nursing Care 2020 |
2020-01-22 |
|
|
| 1204 |
Best Speaker Award for Nursing Care 2020 |
2020-01-22 |
|
|
| 1205 |
Major Nursing Universities in Asia Pacific |
2020-01-22 |
|
|
| 1206 |
Major Nursing Universities in Middle East |
2020-01-22 |
|
|
| 1207 |
Major Nursing Universities in Europe |
2020-01-22 |
|
|
| 1208 |
Major Nursing Universities in USA |
2020-01-22 |
|
|
| 1209 |
The subspecialty of Nursing Field includes |
2020-01-22 |
|
|
| 1210 |
Associations and Societies globally |
2020-01-22 |
|
|
| 1211 |
2020 Best Nursing Schools in World |
2020-01-22 |
|
|
| 1212 |
Development of Nursing Research in future |
2020-01-22 |
|
|
| 1213 |
Quick Look at the Revenue of Nursing Career |
2020-01-22 |
|
|
| 1214 |
Analysis and Aspects of Registered Nurses 2020 Conference |
2020-01-22 |
|
|
| 1215 |
Hospitals Worldwide |
2020-01-22 |
|
|
| 1216 |
Members Associated with Primary Healthcare |
2020-01-22 |
|
|
| 1217 |
Global Vocal Biomarkers Market: |
2020-01-21 |
|
|
| 1218 |
Best Organising Committee Member |
2020-01-21 |
|
|
| 1219 |
Worldwide Market on Pathology |
2020-01-21 |
|
|
| 1220 |
Significance and Scope |
2020-01-21 |
|
|
| 1221 |
3. Session’s Best Presentation Award: |
2020-01-21 |
|
|
| 1222 |
2. Best Poster Award: |
2020-01-21 |
|
|
| 1223 |
1. Young Scientist Award: |
2020-01-21 |
|
|
| 1224 |
Student Ambassador Award |
2020-01-21 |
|
|
| 1225 |
Keynote Speaker Memento |
2020-01-21 |
|
|
| 1226 |
Young Research Award |
2020-01-21 |
|
|
| 1227 |
Conference Opportunities |
2020-01-21 |
|
|
| 1228 |
About the Venue |
2020-01-21 |
|
|
| 1229 |
Scope of Gynecology and Obstetrics |
2020-01-21 |
|
|
| 1230 |
Research Excellence Awards |
2020-01-21 |
|
|
| 1231 |
Pathogenesis And Risk Factors |
2020-01-20 |
|
|
| 1232 |
Further Key Findings from the Report Suggest: |
2020-01-17 |
|
|
| 1233 |
Award recognizes Masters / Ph. D./Post Ph.D |
2020-01-17 |
|
|
| 1234 |
Excellence Award |
2020-01-17 |
|
|
| 1235 |
Out Standing Award |
2020-01-17 |
|
|
| 1236 |
Participant Details |
2020-01-17 |
|
|
| 1237 |
Dubai: The City Above Sky |
2020-01-17 |
|
|
| 1238 |
Program Structure |
2020-01-17 |
|
|
| 1239 |
Track Structure |
2020-01-17 |
|
|
| 1240 |
Notable Speakers of Psychiatry 2019 |
2020-01-17 |
|
|
| 1241 |
Past Conference Report |
2020-01-17 |
|
|
| 1242 |
Benefits for Young Scientist Forum: |
2020-01-17 |
|
|
| 1243 |
Poster presentation Benefits: |
2020-01-17 |
|
|
| 1244 |
Best Poster Award: |
2020-01-17 |
|
|
| 1245 |
Awards: |
2020-01-17 |
|
|
| 1246 |
Market Analysis: Polymers |
2020-01-16 |
|
|
| 1247 |
Smart Polymer Market Size and Trend |
2020-01-16 |
|
|
| 1248 |
Market Value on Nursing |
2020-01-16 |
|
|
| 1249 |
Comparison of laparoscopy vs. Robotics in rectal cancer |
2020-01-13 |
|
|
| 1250 |
Backgorund |
2020-01-13 |
|
|
| 1251 |
Ethical Approval and Consent to Participate |
2020-01-10 |
|
|
| 1252 |
Statistical Methods |
2020-01-09 |
|
|
| 1253 |
Neuroimmunology 2018 Gallery: |
2020-01-08 |
|
|
| 1254 |
Market Sectors |
2020-01-08 |
|
|
| 1255 |
Prevalence of Neurological Disorders |
2020-01-08 |
|
|
| 1256 |
Universities and Colleges: |
2019-12-31 |
|
|
| 1257 |
Why Singapore? |
2019-12-31 |
|
|
| 1258 |
Need of Neurosurgery: |
2019-12-31 |
|
|
| 1259 |
Best Student Presentation Award |
2019-12-30 |
|
|
| 1260 |
Best Speaker Presentation Award |
2019-12-30 |
|
|
| 1261 |
Best Organising Commitee Member |
2019-12-30 |
|
|
| 1262 |
Best Keynote Speaker Presentation Award |
2019-12-30 |
|
|
| 1263 |
The City |
2019-12-19 |
|
|
| 1264 |
Why to Attend? |
2019-12-19 |
|
|
| 1265 |
Why Frankfurt? |
2019-12-19 |
|
|
| 1266 |
Highlights For Smart Materials Conference |
2019-12-19 |
|
|
| 1267 |
Market Analysis Of Laboratory Medicine |
2019-12-19 |
|
|
| 1268 |
Overall Statistics |
2019-12-19 |
|
|
| 1269 |
Best Poster Presentation Award |
2019-12-19 |
|
|
| 1270 |
Best Young Research Forum Award |
2019-12-19 |
|
|
| 1271 |
Best Plenary Award |
2019-12-19 |
|
|
| 1272 |
Best Keynote Award |
2019-12-19 |
|
|
| 1273 |
Best Organizing Committee Member Award |
2019-12-19 |
|
|
| 1274 |
Scholar/ Student Level |
2019-12-19 |
|
|
| 1275 |
Market Growth of Neuroscience |
2019-12-19 |
|
|
| 1276 |
Exceptional Masters/Ph.d./Post Doctorate Proposition Work Presentation in Cancer Science 2020 |
2019-12-18 |
|
|
| 1277 |
Best Poster Presentation in Cancer Science 2020 |
2019-12-18 |
|
|
| 1278 |
Best Keynote Speaker in Cancer Science 2020 |
2019-12-18 |
|
|
| 1279 |
The Exceptional Speaker in Cancer Science 2020 |
2019-12-18 |
|
|
| 1280 |
Researcher Level (The Upcoming Researcher Award) |
2019-12-18 |
|
|
| 1281 |
Proficient Level (The Research Contribution Award) |
2019-12-18 |
|
|
| 1282 |
Master Level (Scientific Service Achievement Award) |
2019-12-18 |
|
|
| 1283 |
Medical Robotics and Computer Assisted Surgery Market Overview: |
2019-12-18 |
|
|
| 1284 |
Why Japan? |
2019-12-18 |
|
|
| 1285 |
Importance |
2019-12-18 |
|
|
| 1286 |
Best Poster Award: Breast Cancer |
2019-12-17 |
|
|
| 1287 |
Categories of the Awards Section are as Follows |
2019-12-17 |
|
|
| 1288 |
Notable Speakers of Cancer Research 2019 |
2019-12-17 |
|
|
| 1289 |
Eminent Organizing Committee Members of Cancer Research 2019 |
2019-12-17 |
|
|
| 1290 |
Overall Statistics |
2019-12-17 |
|
|
| 1291 |
Statistics Of Industries Associated With Proteomics |
2019-12-17 |
|
|
| 1292 |
Best Keynote Speaker |
2019-12-17 |
|
|
| 1293 |
Our Conference Highlights Includes |
2019-12-17 |
|
|
| 1294 |
Key Market Trends |
2019-12-17 |
|
|
| 1295 |
Market Analysis |
2019-12-17 |
|
|
| 1296 |
Notable Speakers of Cancer Science 2019 |
2019-12-17 |
|
|
| 1297 |
Young Researchers Forum (Yrf) |
2019-12-17 |
|
|
| 1298 |
Poster Presentation |
2019-12-13 |
|
|
| 1299 |
Video Presentation |
2019-12-13 |
|
|
| 1300 |
Young Research Forum |
2019-12-13 |
|
|
| 1301 |
Delegate Award |
2019-12-13 |
|
|
| 1302 |
Speaker Awards |
2019-12-13 |
|
|
| 1303 |
Keynote Speaker Awards |
2019-12-13 |
|
|
| 1304 |
Awards |
2019-12-13 |
|
|
| 1305 |
Medicinal Chemistry 2020 |
2019-12-13 |
|
|
| 1306 |
Scope and Importance |
2019-12-13 |
|
|
| 1307 |
Why Tokyo? |
2019-12-13 |
|
|
| 1308 |
Benefits For Young Scientists |
2019-12-13 |
|
|
| 1309 |
Poster presentation Benefits: |
2019-12-13 |
|
|
| 1310 |
YOUNG SCIENTIST RESEARCHER (YRF) |
2019-12-13 |
|
|
| 1311 |
Benefits of Attending Physicians 2020 |
2019-12-13 |
|
|
| 1312 |
SAVE THE DATE for Physicians 2020!!! |
2019-12-13 |
|
|
| 1313 |
Embryological Significance |
2019-12-11 |
|
|
| 1314 |
Top companies in Italy |
2019-12-11 |
|
|
| 1315 |
Top companies around the globe |
2019-12-11 |
|
|
| 1316 |
Top Universities around the globe |
2019-12-11 |
|
|
| 1317 |
Target Audience |
2019-12-11 |
|
|
| 1318 |
Major Neurology and Neurophysiology Associations around the Globe |
2019-12-11 |
|
|
| 1319 |
Glance at Market Share |
2019-12-11 |
|
|
| 1320 |
Importance and Scope |
2019-12-11 |
|
|
| 1321 |
Best Session of the Day |
2019-12-10 |
|
|
| 1322 |
Best Poster Presentation |
2019-12-10 |
|
|
| 1323 |
Best Keynote Presentation |
2019-12-10 |
|
|
| 1324 |
Best Speaker Presentation |
2019-12-10 |
|
|
| 1325 |
Young Scientist |
2019-12-10 |
|
|
| 1326 |
Women Scientist |
2019-12-10 |
|
|
| 1327 |
Scholar/Student Level |
2019-12-10 |
|
|
| 1328 |
High-Profile/Expert Level |
2019-12-10 |
|
|
| 1329 |
Veteran Level |
2019-12-10 |
|
|
| 1330 |
Be one among the aspirants of Advanced Neurology 2020! |
2019-12-10 |
|
|
| 1331 |
Young Scientist Award |
2019-12-10 |
|
|
| 1332 |
Best Poster Award |
2019-12-10 |
|
|
| 1333 |
Young Research Forum Research Award |
2019-12-10 |
|
|
| 1334 |
Outstanding Poster Award for Excellence |
2019-12-10 |
|
|
| 1335 |
Best Organizing Committee Member Award for Excellence |
2019-12-10 |
|
|
| 1336 |
Outstanding Speaker Award for Excellence |
2019-12-10 |
|
|
| 1337 |
Best Keynote Speaker Awards for Excellence |
2019-12-10 |
|
|
| 1338 |
Materials Need for Participation |
2019-12-10 |
|
|
| 1339 |
Benefits |
2019-12-10 |
|
|
| 1340 |
Nairs Classification |
2019-12-09 |
|
|
| 1341 |
Selection of Cases |
2019-12-09 |
|
|
| 1342 |
Data and Methodology |
2019-12-09 |
|
|
| 1343 |
Funding source |
2019-11-07 |
|
|
| 1344 |
Funding Sources/Disclosures |
2019-10-31 |
|
|
| 1345 |
Other Biomedical Named Entity Recognition and Normalization |
2019-10-31 |
|
|
| 1346 |
Gene Normalization |
2019-10-31 |
|
|
| 1347 |
Gene Mention Recognition |
2019-10-31 |
|
|
| 1348 |
Appendix |
2019-10-31 |
|
|
| 1349 |
Consent to Publish |
2019-09-19 |
|
|
| 1350 |
Consent to Participate |
2019-09-19 |
|
|
| 1351 |
Case Destion |
2019-09-06 |
|
|
| 1352 |
Disclamier |
2019-09-05 |
|
|
| 1353 |
Settings and Design |
2019-09-03 |
|
|
| 1354 |
Context |
2019-09-03 |
|
|
| 1355 |
Case Description |
2019-09-02 |
|
|
| 1356 |
Authors' Contributions |
2019-09-02 |
|
|
| 1357 |
Authors’ Contributions |
2019-09-02 |
|
|
| 1358 |
Treatment Implications |
2019-08-28 |
|
|
| 1359 |
Mechanisms of Action |
2019-08-28 |
|
|
| 1360 |
Strengths and Weaknesses |
2019-08-26 |
|
|
| 1361 |
Disclaimer |
2019-08-26 |
|
|
| 1362 |
Thyroid Hormone |
2019-08-26 |
|
|
| 1363 |
Statistic Analysis |
2019-08-26 |
|
|
| 1364 |
Most Common Cardiovascular Risk Factors |
2019-08-26 |
|
|
| 1365 |
Limitations of the Present Study |
2019-08-03 |
|
|
| 1366 |
Acronyms and Abbreviations |
2019-07-29 |
|
|
| 1367 |
WayForward |
2019-07-24 |
|
|
| 1368 |
Conflict of Interests |
2019-07-18 |
|
|
| 1369 |
Advantages Of Natural Nail |
2019-07-18 |
|
|
| 1370 |
Exclusion criteria |
2019-07-18 |
|
|
| 1371 |
Inclusion Criteria |
2019-07-18 |
|
|
| 1372 |
Surgical Procedure |
2019-07-05 |
|
|
| 1373 |
Case Report |
2019-07-05 |
|
|
| 1374 |
Tubal Infertility |
2019-07-04 |
|
|
| 1375 |
Male Factor Infertility |
2019-07-04 |
|
|
| 1376 |
Endometriosis |
2019-07-04 |
|
|
| 1377 |
Unexplained Infertility |
2019-07-04 |
|
|
| 1378 |
Case Scenario |
2019-06-27 |
|
|
| 1379 |
heading |
2019-06-12 |
|
|
| 1380 |
Results and Conclusions |
2019-06-10 |
|
|
| 1381 |
Role Of Ranolazine |
2019-06-10 |
|
|
| 1382 |
Traditional Treatments For NHL |
2019-06-07 |
|
|
| 1383 |
Traditional Treatments For Nhl< |
2019-06-07 |
|
|
| 1384 |
NHL Origiates in gremiaERMINAL CENTERS |
2019-06-07 |
|
|
| 1385 |
Future Research Prospects |
2019-06-07 |
|
|
| 1386 |
Etiopathogenesis |
2019-06-07 |
|
|
| 1387 |
Subject And Methods |
2019-05-27 |
|
|
| 1388 |
Patients |
2019-05-27 |
|
|
| 1389 |
Epidemiology and Clinical Presentation |
2019-05-24 |
|
|
| 1390 |
Roshan Noor Mohamed |
2019-05-24 |
|
|
| 1391 |
O.A.R.S |
2019-05-24 |
|
|
| 1392 |
Elicit Change Talk |
2019-05-24 |
|
|
| 1393 |
Principles of MI |
2019-05-24 |
|
|
| 1394 |
Spirit of MI |
2019-05-24 |
|
|
| 1395 |
Elements of Motivational Interviewing |
2019-05-24 |
|
|
| 1396 |
What is MI? |
2019-05-24 |
|
|
| 1397 |
Literature Review in Relation to Dentistry |
2019-05-24 |
|
|
| 1398 |
Ethics Approval and Consent to Participate |
2019-05-24 |
|
|
| 1399 |
Interventions |
2019-05-24 |
|
|
| 1400 |
Local Hemostatic Agents |
2019-05-15 |
|
|
| 1401 |
Surgical Treatment |
2019-05-15 |
|
|
| 1402 |
Local Anesthesia |
2019-05-15 |
|
|
| 1403 |
Potential Food Applications |
2019-05-14 |
|
|
| 1404 |
Properties of Biosurfactants |
2019-05-14 |
|
|
| 1405 |
Final Diagnosis |
2019-05-08 |
|
|
| 1406 |
Conclusions and Future work |
2019-05-02 |
|
|
| 1407 |
Case Study for Design Principles for Open eHealth Platform |
2019-05-02 |
|
|
| 1408 |
National eHealth in Slovenia |
2019-05-02 |
|
|
| 1409 |
Disclosures/Conflicts of Interests |
2019-05-02 |
|
|
| 1410 |
Descriptions Of The Everyday Reality Through Case Examples |
2019-05-02 |
|
|
| 1411 |
Questionnaire Design and Sampling |
2019-05-02 |
|
|
| 1412 |
Theoretical Framework |
2019-05-02 |
|
|
| 1413 |
Multi-feature Service for Smoking Cessation |
2019-05-02 |
|
|
| 1414 |
Appendix III: Summary of Studies |
2019-05-02 |
|
|
| 1415 |
Appendix II: Conceptual Map |
2019-05-02 |
|
|
| 1416 |
Appendix I: Search Terms |
2019-05-02 |
|
|
| 1417 |
Author Contributions |
2019-05-02 |
|
|
| 1418 |
Author's Contributions |
2019-05-01 |
|
|
| 1419 |
Immunological Evaluation |
2019-05-01 |
|
|
| 1420 |
Question |
2019-04-26 |
|
|
| 1421 |
Operative Procedure |
2019-04-16 |
|
|
| 1422 |
Value Of Pre-Operative Planning To The Surgeon And Trainee |
2019-04-16 |
|
|
| 1423 |
Third Step |
2019-04-16 |
|
|
| 1424 |
Second Step |
2019-04-16 |
|
|
| 1425 |
Medications |
2019-04-16 |
|
|
| 1426 |
First Step |
2019-04-16 |
|
|
| 1427 |
Some Facts About Kuwait And The Prevalence Of Knee OA |
2019-04-16 |
|
|
| 1428 |
Declaration of Interest |
2019-04-15 |
|
|
| 1429 |
Purpose |
2019-04-15 |
|
|
| 1430 |
Classification of Renal Vein Anomalies |
2019-04-15 |
|
|
| 1431 |
Embryogenesis of left retro-aortic renal vein Draining into left common iliac vein anomaly |
2019-04-15 |
|
|
| 1432 |
Statistical Analyses |
2019-03-29 |
|
|
| 1433 |
The H@H Project Infrastructure |
2019-03-20 |
|
|
| 1434 |
Example for Re-Engineering an ISO Specification Using the Interoperability Reference Architecture Model |
2019-03-20 |
|
|
| 1435 |
The Interoperability Reference Architecture Model Standard |
2019-03-20 |
|
|
| 1436 |
The Transformative Healthcare Interoperability Challenge |
2019-03-20 |
|
|
| 1437 |
The Transformation of the Healthcare Eco-System – A System-Theoretical Approach |
2019-03-20 |
|
|
| 1438 |
Better Health |
2019-03-20 |
|
|
| 1439 |
Evolving Standards |
2019-03-20 |
|
|
| 1440 |
The World as it is |
2019-03-20 |
|
|
| 1441 |
What these Changes Mean to Better Health |
2019-03-20 |
|
|
| 1442 |
A Changing World |
2019-03-20 |
|
|
| 1443 |
Related Works |
2019-03-19 |
|
|
| 1444 |
Clinical Applications of Diode Lasers |
2019-03-19 |
|
|
| 1445 |
Declaration of Interests |
2019-03-19 |
|
|
| 1446 |
Paper Context |
2019-03-19 |
|
|
| 1447 |
Funding Information |
2019-03-19 |
|
|
| 1448 |
Ethics and Consent |
2019-03-19 |
|
|
| 1449 |
The Data |
2019-03-19 |
|
|
| 1450 |
The Model |
2019-03-19 |
|
|
| 1451 |
Human Subjects and Method |
2019-03-19 |
|
|
| 1452 |
New Waves |
2019-03-19 |
|
|
| 1453 |
Satellite Communication of Homecare Systems Showed Needs of ASP |
2019-03-19 |
|
|
| 1454 |
The Introduction of Cloud Technology in EPR and PACS Sharing System |
2019-03-19 |
|
|
| 1455 |
Thin-client System |
2019-03-19 |
|
|
| 1456 |
Standardization |
2019-03-19 |
|
|
| 1457 |
Abbreviations and Acronyms Used |
2019-03-19 |
|
|
| 1458 |
International Interoperability |
2019-03-18 |
|
|
| 1459 |
Private and Security Interoperability |
2019-03-18 |
|
|
| 1460 |
Bussiness Interoperability |
2019-03-18 |
|
|
| 1461 |
Consumer Interoperability |
2019-03-18 |
|
|
| 1462 |
Stackholder Interoperability |
2019-03-18 |
|
|
| 1463 |
Functional Interoperability |
2019-03-18 |
|
|
| 1464 |
Semantic Interoperability |
2019-03-18 |
|
|
| 1465 |
Definitions of Interoperability |
2019-03-18 |
|
|
| 1466 |
Complementary Treatments |
2019-03-14 |
|
|
| 1467 |
Psychopharmacotherapy For Alzheimer Disease And Other Dementia |
2019-03-14 |
|
|
| 1468 |
Dementia Variations With Age of Occurence |
2019-03-14 |
|
|
| 1469 |
On Neurodegenerative Dementia |
2019-03-14 |
|
|
| 1470 |
On Cognitive Impairment |
2019-03-14 |
|
|
| 1471 |
Contributing Diseases |
2019-03-14 |
|
|
| 1472 |
Approach To Diagnosis |
2019-03-14 |
|
|
| 1473 |
Mental Disorder Classification |
2019-03-14 |
|
|
| 1474 |
Staging Of The Disease |
2019-03-14 |
|
|
| 1475 |
Signs and Symptoms |
2019-03-14 |
|
|
| 1476 |
Epidemiology of the Disease |
2019-03-14 |
|
|
| 1477 |
A Brief History |
2019-03-14 |
|
|
| 1478 |
Modeling Health Systems |
2019-03-08 |
|
|
| 1479 |
Contemporary Developments and Reflections on Professor Zvárová’s Fields of Interest |
2019-03-08 |
|
|
| 1480 |
Digital Health Directions |
2019-03-08 |
|
|
| 1481 |
Last Conversations |
2019-03-08 |
|
|
| 1482 |
Summary and Conclusion |
2019-03-08 |
|
|
| 1483 |
Future of Health Informatics – Major Issues Raised by Professional Women |
2019-03-08 |
|
|
| 1484 |
Perspectives for Future Development of Medical Informatics |
2019-03-08 |
|
|
| 1485 |
Medical Informatics Education Today |
2019-03-08 |
|
|
| 1486 |
Medical Informatics Curricula (Example of Bosnia and Herzegovina) |
2019-03-08 |
|
|
| 1487 |
The Bologna Process and Medical Informatics |
2019-03-08 |
|
|
| 1488 |
Medical Informatics – Educational Concepts |
2019-03-08 |
|
|
| 1489 |
Present and Future of Decision Support |
2019-03-08 |
|
|
| 1490 |
Data, Information and Knowledge |
2019-03-08 |
|
|
| 1491 |
In What Aspect is the Proposed Solution Actually Innovative? |
2019-03-08 |
|
|
| 1492 |
What Changes are Expected Due to the Project? |
2019-03-08 |
|
|
| 1493 |
What is the Goal of the Project? |
2019-03-08 |
|
|
| 1494 |
Problem Description |
2019-03-08 |
|
|
| 1495 |
Cadaveric Case Presentation |
2019-03-07 |
|
|
| 1496 |
Hypothesis Testing |
2019-03-07 |
|
|
| 1497 |
Partial Least Squares |
2019-03-07 |
|
|
| 1498 |
Variable Selection based on Maximal Conditional Entropy |
2019-03-07 |
|
|
| 1499 |
Principal Component Analysis |
2019-03-07 |
|
|
| 1500 |
Overview of Complexity Reduction |
2019-03-07 |
|
|
| 1501 |
Big Data in Biomedicine |
2019-03-07 |
|
|
| 1502 |
Patient Portals and Patient Empowerment |
2019-03-07 |
|
|
| 1503 |
From eHealth to ePatient |
2019-03-07 |
|
|
| 1504 |
EHR Systems Standards and Solutions |
2019-03-07 |
|
|
| 1505 |
EHR Systems‘ Interoperability |
2019-03-07 |
|
|
| 1506 |
EHR Systems’ Objectives and Requirements |
2019-03-07 |
|
|
| 1507 |
Conclusion and Final Considerations |
2019-03-07 |
|
|
| 1508 |
Clinical Outcomes of Ondansetron Administration with Elective Cesarean Delivery |
2019-03-07 |
|
|
| 1509 |
Photo Gallery |
2019-03-02 |
|
|
| 1510 |
Personality of Jana Zvárová |
2019-03-02 |
|
|
| 1511 |
Recognition of the Professional Prestige of Jana Zvárová |
2019-03-02 |
|
|
| 1512 |
Full Affirmation Period |
2019-03-02 |
|
|
| 1513 |
Ascension Period |
2019-03-02 |
|
|
| 1514 |
Early Work: Studies and Scientific Pursuits |
2019-03-02 |
|
|
| 1515 |
Human Subjects Protections |
2019-02-28 |
|
|
| 1516 |
Clinical Relevance Statement |
2019-02-28 |
|
|
| 1517 |
Limitations of Study |
2019-02-23 |
|
|
| 1518 |
Vibrational Oct Measurements |
2019-02-22 |
|
|
| 1519 |
Competing of Interests |
2019-02-11 |
|
|
| 1520 |
Risk Factors and Management |
2019-01-29 |
|
|
| 1521 |
How should evaluation start? |
2019-01-29 |
|
|
| 1522 |
Surgical Technique |
2019-01-28 |
|
|
| 1523 |
Contribution of the Authors |
2019-01-25 |
|
|
| 1524 |
Case Presentation and Observations |
2019-01-25 |
|
|
| 1525 |
Role Of Eosinophils In Cancer |
2019-01-23 |
|
|
| 1526 |
Eosinophils At Tumor Site |
2019-01-23 |
|
|
| 1527 |
MBL Other Than CLL-LIKE |
2019-01-22 |
|
|
| 1528 |
CLL-LIKE MBL |
2019-01-22 |
|
|
| 1529 |
Contemporary Therapeutic Agent |
2019-01-22 |
|
|
| 1530 |
Therapeutic Protocols |
2019-01-22 |
|
|
| 1531 |
Prognostic Determinants |
2019-01-22 |
|
|
| 1532 |
Radiological Investigations |
2019-01-22 |
|
|
| 1533 |
Genetic Modifications |
2019-01-22 |
|
|
| 1534 |
Comparison And Contrast |
2019-01-22 |
|
|
| 1535 |
Creative Inquiry Movements |
2019-01-22 |
|
|
| 1536 |
Activity Theory |
2019-01-22 |
|
|
| 1537 |
Construction Theory |
2019-01-22 |
|
|
| 1538 |
Immune Phenotypes In Lymphoblastic Lymphoma |
2019-01-22 |
|
|
| 1539 |
Tumour Morphology |
2019-01-22 |
|
|
| 1540 |
Disease Characterization |
2019-01-22 |
|
|
| 1541 |
Epidemiological view of colistin resistance in Faisalaabad, pakistan |
2019-01-12 |
|
|
| 1542 |
Plasmid-Mediated Colistin Resistance |
2019-01-12 |
|
|
| 1543 |
Colistin |
2019-01-12 |
|
|
| 1544 |
Antimicrobial Resistance (Amr) |
2019-01-12 |
|
|
| 1545 |
Suggestions |
2019-01-11 |
|
|
| 1546 |
Author’s Contributions |
2019-01-11 |
|
|
| 1547 |
Quality of Incision |
2019-01-11 |
|
|
| 1548 |
Histological Analysis |
2019-01-11 |
|
|
| 1549 |
Diffuse Oral Mucosal Pigmentation |
2019-01-11 |
|
|
| 1550 |
Causes of Melanocytic Pigmentation |
2019-01-11 |
|
|
| 1551 |
Reactive Melanocytic Pigmentation |
2019-01-11 |
|
|
| 1552 |
Disclosure of Interest |
2019-01-11 |
|
|
| 1553 |
Case Study-4 |
2019-01-11 |
|
|
| 1554 |
Ua/Nstemi |
2019-01-11 |
|
|
| 1555 |
Stemi |
2019-01-11 |
|
|
| 1556 |
Oxalate-Degrading Bacteria as new Therapeutic Tools for Preventing Kidney Stones |
2019-01-11 |
|
|
| 1557 |
Therapeutic Options and Methods of Prohibition of Kidney Stones |
2019-01-11 |
|
|
| 1558 |
Mechanism of Kidney Stone Formation |
2019-01-11 |
|
|
| 1559 |
Case Study-3 |
2019-01-10 |
|
|
| 1560 |
Case Study-2 |
2019-01-10 |
|
|
| 1561 |
Case Study-1 |
2019-01-10 |
|
|
| 1562 |
Methods and Strategies for Sand Search |
2019-01-10 |
|
|
| 1563 |
Regional Geology and Site Description |
2019-01-10 |
|
|
| 1564 |
Eestimation of Mineral Resources and Mineral Reserves |
2019-01-10 |
|
|
| 1565 |
Planning and Performing of Mineral Projects |
2019-01-10 |
|
|
| 1566 |
Therapeutic Intervention |
2019-01-10 |
|
|
| 1567 |
Prognostic Guide |
2019-01-10 |
|
|
| 1568 |
Radiographic Assay |
2019-01-10 |
|
|
| 1569 |
Immune Histochemistry |
2019-01-10 |
|
|
| 1570 |
Variants of Myoepithelioma |
2019-01-10 |
|
|
| 1571 |
Microscopy |
2019-01-10 |
|
|
| 1572 |
Naked Eye Inspection |
2019-01-10 |
|
|
| 1573 |
Histogenesis |
2019-01-10 |
|
|
| 1574 |
Disease Characteristics |
2019-01-10 |
|
|
| 1575 |
Rethinking Vaccine Design |
2019-01-10 |
|
|
| 1576 |
Pyrexias of Unknown Origin |
2019-01-10 |
|
|
| 1577 |
Zoonotic Transmission? |
2019-01-10 |
|
|
| 1578 |
Cross-Reactivity with ZIKA |
2019-01-10 |
|
|
| 1579 |
A New Dengue Serotype |
2019-01-10 |
|
|
| 1580 |
Lack of Specific Therapy |
2019-01-10 |
|
|
| 1581 |
Dengue Infection |
2019-01-10 |
|
|
| 1582 |
Dengue Virus |
2019-01-10 |
|
|
| 1583 |
List of Abbreviations |
2019-01-08 |
|
|
| 1584 |
Perspective |
2019-01-07 |
|
|
| 1585 |
Aim and Objectives |
2019-01-07 |
|
|
| 1586 |
Variation in Ear Shape |
2019-01-07 |
|
|
| 1587 |
Frankfort Horizontal |
2019-01-07 |
|
|
| 1588 |
Anatomical Landmarks of the Ear |
2019-01-07 |
|
|
| 1589 |
Anatomy of the External Ear |
2019-01-07 |
|
|
| 1590 |
Methods and Materials |
2019-01-07 |
|
|
| 1591 |
Declaration Of Interest |
2018-12-19 |
|
|
| 1592 |
Quantification Analysis For Total Alkaloids |
2018-12-17 |
|
|
| 1593 |
Aim of the Work |
2018-12-14 |
|
|
| 1594 |
Study Limitation |
2018-12-14 |
|
|
| 1595 |
Statistics |
2018-12-03 |
|
|
| 1596 |
Electrolyte-Layer Free Fuel Cell |
2018-11-24 |
|
|
| 1597 |
Conventional Solid Oxide Fuel Cell |
2018-11-24 |
|
|
| 1598 |
Outline of Experiment |
2018-11-24 |
|
|
| 1599 |
Critical Reynolds Number Values, Poiseuille Number and Ducts Cross-Section Curvature |
2018-11-24 |
|
|
| 1600 |
Experimental Friction Curves in Ducts of Complex Cross-Section Shape |
2018-11-24 |
|
|
| 1601 |
Key Messages |
2018-11-16 |
|
|
| 1602 |
Methodolgy |
2018-11-16 |
|
|
| 1603 |
Limits of the Study |
2018-11-16 |
|
|
| 1604 |
Data-Gathering Tools |
2018-11-16 |
|
|
| 1605 |
Acknowledgments |
2018-11-15 |
|
|
| 1606 |
Data Availability |
2018-11-12 |
|
|
| 1607 |
Consent to Participate and Publish |
2018-11-05 |
|
|
| 1608 |
Funding Statement |
2018-11-05 |
|
|
| 1609 |
Acknowledgment |
2018-11-05 |
|
|
| 1610 |
Limitation of the Study |
2018-11-05 |
|
|
| 1611 |
Limitations and Suggestion |
2018-11-05 |
|
|
| 1612 |
Literature Review and Discussion |
2018-11-05 |
|
|
| 1613 |
Introduction and Background |
2018-11-05 |
|
|
| 1614 |
What Dose Paper Adds? |
2018-10-30 |
|
|
| 1615 |
PCB Congener Profile and Homologues in Galatea Paradoxa from Ada in Ghana |
2018-10-25 |
|
|
| 1616 |
Risk Assessment of PCBs in Galatea paradoxa from Ada in Ghana and Health Implications on Consumers |
2018-10-25 |
|
|
| 1617 |
Effects Of Exercise On Protein Synthesis |
2018-10-17 |
|
|
| 1618 |
Phosphatidic Acid, Protein Synthesis From Resistance Training |
2018-10-17 |
|
|
| 1619 |
Leucine Protein Synthesis And Insulin Release |
2018-10-17 |
|
|
| 1620 |
Results and Observation |
2018-10-05 |
|
|
| 1621 |
Hazard Index (HI) of Pcbs in Galatea paradoxa from Ada in Ghana |
2018-09-27 |
|
|
| 1622 |
Toxicity Equivalents (TEQs) Concentration of PCB 118 |
2018-09-27 |
|
|
| 1623 |
Study Results in the Context of Published Studies |
2018-09-27 |
|
|
| 1624 |
PCB Congener Profile and Homologues in Galatea Paradoxa from Ada in Ghana |
2018-09-27 |
|
|
| 1625 |
Distribution Pattern of Pcb Congeners in Galatea paradoxa from Ada in Ghana During the Wet and Dry Seasons |
2018-09-27 |
|
|
| 1626 |
Procedure Used to Determine Hazard Index (Hi) and Toxic Equivalents (TEQs) of the Samples |
2018-09-27 |
|
|
| 1627 |
Computation of Recovery and Precision Estimation of Samples |
2018-09-27 |
|
|
| 1628 |
Quality Assurance |
2018-09-27 |
|
|
| 1629 |
Sample Collection and Processing |
2018-09-27 |
|
|
| 1630 |
Disclosure Statement |
2018-09-25 |
|
|
| 1631 |
Future Aspects of Crispr-Cas9 Technology |
2018-09-21 |
|
|
| 1632 |
Applications for Crispr-Cas9 Technology |
2018-09-21 |
|
|
| 1633 |
Mechanism |
2018-09-21 |
|
|
| 1634 |
How Was Crispr-Cas9 Developed? |
2018-09-21 |
|
|
| 1635 |
Who Invented Crispr-Cas9? |
2018-09-21 |
|
|
| 1636 |
CRISPR-cas9 |
2018-09-21 |
|
|
| 1637 |
TALENs |
2018-09-21 |
|
|
| 1638 |
ZFNs |
2018-09-21 |
|
|
| 1639 |
New Tools In DNA Editing |
2018-09-21 |
|
|
| 1640 |
The Story Of DNA Manipulation |
2018-09-21 |
|
|
| 1641 |
The Human Genome Project |
2018-09-21 |
|
|
| 1642 |
DNA: The Master Molecule |
2018-09-21 |
|
|
| 1643 |
History |
2018-09-21 |
|
|
| 1644 |
Case Details |
2018-09-21 |
|
|
| 1645 |
Net Trend |
2018-09-21 |
|
|
| 1646 |
Controversies and Variations in Practice |
2018-09-21 |
|
|
| 1647 |
Risks and Complications |
2018-09-21 |
|
|
| 1648 |
Indications |
2018-09-21 |
|
|
| 1649 |
Historical Perspective |
2018-09-21 |
|
|
| 1650 |
Experimental Details |
2018-09-21 |
|
|
| 1651 |
Nursing Implications |
2018-09-18 |
|
|
| 1652 |
EPS Analysis |
2018-09-11 |
|
|
| 1653 |
Microphytobenthos Observations |
2018-09-11 |
|
|
| 1654 |
Laboratory Analysis |
2018-09-11 |
|
|
| 1655 |
Study Period |
2018-09-06 |
|
|
| 1656 |
Humphrey |
2018-08-23 |
|
|
| 1657 |
Core Tip |
2018-08-22 |
|
|
| 1658 |
Prediction |
2018-08-22 |
|
|
| 1659 |
Risk Factors |
2018-08-22 |
|
|
| 1660 |
Ethics Approval |
2018-08-10 |
|
|
| 1661 |
Conflict Of Interest Disclosure |
2018-07-17 |
|
|
| 1662 |
Previous Presentations |
2018-07-13 |
|
|
| 1663 |
Research Methodology |
2018-07-13 |
|
|
| 1664 |
Limitation of study |
2018-07-13 |
|
|
| 1665 |
Materials and Method |
2018-07-11 |
|
|
| 1666 |
Material |
2018-07-11 |
|
|
| 1667 |
Aims & Objective |
2018-07-11 |
|
|
| 1668 |
Future of DE |
2018-07-06 |
|
|
| 1669 |
Electricity Generator Using DE |
2018-07-06 |
|
|
| 1670 |
Development of DE Actuators |
2018-07-06 |
|
|
| 1671 |
DE Summary and Operating Principle |
2018-07-06 |
|
|
| 1672 |
Results and Observations |
2018-07-02 |
|
|
| 1673 |
Conflict of Interest and Source of Funding |
2018-06-26 |
|
|
| 1674 |
Laboratory |
2018-06-26 |
|
|
| 1675 |
Conclusion And Perspectives |
2018-06-25 |
|
|
| 1676 |
Study On The Interactions Between Rimonabant And Cb1 Receptor By Means Of Molecular Modeling |
2018-06-25 |
|
|
| 1677 |
Relationship Between Structure and Activity Of Rimonbant and Taranabant |
2018-06-25 |
|
|
| 1678 |
ENDOCANNABINOID SYSTEM AND EATING ATTITUDES |
2018-06-25 |
|
|
| 1679 |
Types of cannabinoid receptors |
2018-06-25 |
|
|
| 1680 |
ENDOGENOUS CANNABINOIDS |
2018-06-25 |
|
|
| 1681 |
ENDOCANNABINOID SYSTEM (ECS) |
2018-06-25 |
|
|
| 1682 |
Surgical Treatment |
2018-06-05 |
|
|
| 1683 |
First-Time Dislocation |
2018-06-05 |
|
|
| 1684 |
Nonoperative Treatment |
2018-06-05 |
|
|
| 1685 |
Outcome Measurement System |
2018-06-05 |
|
|
| 1686 |
Pathoanatomy of Atraumatic Instability |
2018-06-05 |
|
|
| 1687 |
Pathoanatomy of Traumatic Posterior Instability |
2018-06-05 |
|
|
| 1688 |
Pathoanatomy of Traumatic Anterior Instability |
2018-06-05 |
|
|
| 1689 |
Epidemiology |
2018-06-05 |
|
|
| 1690 |
Description of the Area and Geological Setting |
2018-06-04 |
|
|
| 1691 |
Discussion and Results |
2018-06-04 |
|
|
| 1692 |
Subjects and Method |
2018-05-30 |
|
|
| 1693 |
Aim of the Study |
2018-05-30 |
|
|
| 1694 |
Significant of Study |
2018-05-30 |
|
|
| 1695 |
Clinical Implications |
2018-05-30 |
|
|
| 1696 |
Conclusion And Future Perspectives |
2018-05-30 |
|
|
| 1697 |
Target Drug: Solanesol |
2018-05-30 |
|
|
| 1698 |
Experimental Animal Model For Hd |
2018-05-30 |
|
|
| 1699 |
Mitochondrial Dysfunction & Hd |
2018-05-30 |
|
|
| 1700 |
Huntington’s Disease: An Overview |
2018-05-30 |
|
|
| 1701 |
Implications for Nursing |
2018-05-30 |
|
|
| 1702 |
Process Delivery |
2018-05-30 |
|
|
| 1703 |
Developing the Infrastructure |
2018-05-30 |
|
|
| 1704 |
Results:Conceptions of Mechanism of Action |
2018-05-24 |
|
|
| 1705 |
Patient Group Directions(PGDS) |
2018-05-24 |
|
|
| 1706 |
‘Forward Thinking’ and ‘Forward-Doing’ |
2018-05-24 |
|
|
| 1707 |
Chronic kidney Disease (CKD) |
2018-05-24 |
|
|
| 1708 |
Miscellaneous Narrations from Some Reported Cases and Discussions |
2018-05-24 |
|
|
| 1709 |
Results/Literature Review |
2018-05-24 |
|
|
| 1710 |
Taking Credit for Burnup |
2018-05-10 |
|
|
| 1711 |
Fresh Fuel |
2018-05-10 |
|
|
| 1712 |
Analysis |
2018-05-10 |
|
|
| 1713 |
Contribution statement |
2018-05-04 |
|
|
| 1714 |
Availability of Data and Materials |
2018-05-04 |
|
|
| 1715 |
Animal Subjects |
2018-05-04 |
|
|
| 1716 |
Human Subjects |
2018-05-04 |
|
|
| 1717 |
Consent and Approval |
2018-05-04 |
|
|
| 1718 |
Ethics and Consent to Participate |
2018-05-04 |
|
|
| 1719 |
Future Scope |
2018-05-04 |
|
|
| 1720 |
Physiological Functions of Selenium |
2018-05-04 |
|
|
| 1721 |
Literature Review - Selenium |
2018-05-04 |
|
|
| 1722 |
Discussion & Conclusion |
2018-05-04 |
|
|
| 1723 |
Poisson process simulation |
2018-05-04 |
|
|
| 1724 |
Circadian rhythm of cyanobacteria |
2018-05-04 |
|
|
| 1725 |
Structure of a binary digit of memory in a cell |
2018-05-04 |
|
|
| 1726 |
Dear Editor |
2018-04-27 |
|
|
| 1727 |
Laboratory Examinations |
2018-04-19 |
|
|
| 1728 |
Caution in the use of Bio-Fertilizers |
2018-04-12 |
|
|
| 1729 |
Limitation of Bio-Fertilizer |
2018-04-12 |
|
|
| 1730 |
Importance of Bio-Fertilizers |
2018-04-12 |
|
|
| 1731 |
The Role of Bio-Fertilizers in Enhancing Plant Tolerance to Environmental Stress |
2018-04-12 |
|
|
| 1732 |
Microorganisms used in Bio-Fertilizer |
2018-04-12 |
|
|
| 1733 |
Types of Bio-Fertilizers and How they Work |
2018-04-12 |
|
|
| 1734 |
Differences between Bio-Fertilizer and Organic Fertilizer |
2018-04-12 |
|
|
| 1735 |
What is Bio-Fertilizer? |
2018-04-12 |
|
|
| 1736 |
Soil Fertility |
2018-04-12 |
|
|
| 1737 |
Contribution |
2018-04-12 |
|
|
| 1738 |
Conflict-of-Interest Disclosure |
2018-04-12 |
|
|
| 1739 |
Review of Literature |
2018-04-12 |
|
|
| 1740 |
TTIs and Mass Production |
2018-04-12 |
|
|
| 1741 |
Intelligent Packaging |
2018-04-12 |
|
|
| 1742 |
Cold Chains and Storage |
2018-04-12 |
|
|
| 1743 |
Re-Emerging Disease |
2018-04-12 |
|
|
| 1744 |
Diagnosis of Avian Influenza A Virus |
2018-04-12 |
|
|
| 1745 |
Avian Influenza A Virus |
2018-04-12 |
|
|
| 1746 |
Researcher Exertion |
2018-04-12 |
|
|
| 1747 |
Scope of the Clinical Microbiology and Infectious Diseases |
2018-04-12 |
|
|
| 1748 |
Clinical Application |
2018-04-12 |
|
|
| 1749 |
Declare of Interest Statement |
2018-04-11 |
|
|
| 1750 |
Future needs for this Area of Research |
2018-04-11 |
|
|
| 1751 |
Some Medicinal Plants with Anti-Fertility Potential |
2018-04-11 |
|
|
| 1752 |
POTENTIAL CONFLICTS OF INTEREST |
2018-04-09 |
|
|
| 1753 |
Skin Typing |
2018-04-09 |
|
|
| 1754 |
Fractional Thermolysis |
2018-04-09 |
|
|
| 1755 |
Results and Management |
2018-04-09 |
|
|
| 1756 |
Financial Disclosures |
2018-04-09 |
|
|
| 1757 |
Complications |
2018-04-06 |
|
|
| 1758 |
Funding/Support |
2018-04-06 |
|
|
| 1759 |
Suggestion for Further Studies |
2018-04-06 |
|
|
| 1760 |
Human and Animal Rights |
2018-04-06 |
|
|
| 1761 |
Methods and Patients |
2018-04-06 |
|
|
| 1762 |
Result |
2018-04-06 |
|
|
| 1763 |
Ethical considerations |
2018-04-06 |
|
|
| 1764 |
Implications for Future |
2018-04-03 |
|
|
| 1765 |
Inability to Cope with Disappointments |
2018-04-03 |
|
|
| 1766 |
Academic Stress, Anxiety and Depression Among Students |
2018-04-03 |
|
|
| 1767 |
Parental Pressure |
2018-04-03 |
|
|
| 1768 |
Reports on Suicide And Parental Pressure Among Children Across India |
2018-04-03 |
|
|
| 1769 |
At-Risk and Risky Homeless Youth |
2018-04-02 |
|
|
| 1770 |
Gender and Victimization |
2018-04-02 |
|
|
| 1771 |
Implications for Practice |
2018-04-02 |
|
|
| 1772 |
Ancillary Measures Pending Definitive Revascularization |
2018-03-28 |
|
|
| 1773 |
Anticoagulation |
2018-03-28 |
|
|
| 1774 |
Initial Management |
2018-03-28 |
|
|
| 1775 |
Echocardiography |
2018-03-28 |
|
|
| 1776 |
Definitive Diagnostic Imaging |
2018-03-28 |
|
|
| 1777 |
Determining the Level of Occlusion |
2018-03-28 |
|
|
| 1778 |
Classification of ALI |
2018-03-28 |
|
|
| 1779 |
Clinical Assessment |
2018-03-28 |
|
|
| 1780 |
Presentation |
2018-03-28 |
|
|
| 1781 |
Benzodiazepines |
2018-03-27 |
|
|
| 1782 |
Growth-Differentiation Factor-15 in CV Prediction |
2018-03-27 |
|
|
| 1783 |
Association between Growth-Differentiation Factor-15 and CV Diseases |
2018-03-27 |
|
|
| 1784 |
Biological Role and Function of Growth-Differentiation Factor-15 |
2018-03-27 |
|
|
| 1785 |
Electrochemical Process |
2018-03-22 |
|
|
| 1786 |
Some Of The Major Treatments Of Oil Produced Water |
2018-03-22 |
|
|
| 1787 |
Oil and Grease Content (Og) |
2018-03-22 |
|
|
| 1788 |
Limitations Of The Oil Production Industry And The Wastewater Treatment |
2018-03-22 |
|
|
| 1789 |
Adaptive Capacity Map |
2018-03-22 |
|
|
| 1790 |
Human Activities Sensitivity Maps |
2018-03-22 |
|
|
| 1791 |
Generating the Composite Maps for the Vulnerability Assessment |
2018-03-22 |
|
|
| 1792 |
Study Region |
2018-03-22 |
|
|
| 1793 |
Gratitude |
2018-03-20 |
|
|
| 1794 |
Data Management and Analysis Plan |
2018-03-15 |
|
|
| 1795 |
Case Summary |
2018-03-15 |
|
|
| 1796 |
Experimental Therapies directed against Triplet Repeats |
2018-03-03 |
|
|
| 1797 |
Trinucleotides Repeats Diseases |
2018-03-03 |
|
|
| 1798 |
Dynamic Mutations |
2018-03-03 |
|
|
| 1799 |
Treatment and Interventions |
2018-03-02 |
|
|
| 1800 |
Memory Problems, Suggestibility, and Confabulation |
2018-03-02 |
|
|
| 1801 |
Adaptive Functioning Considerations |
2018-03-02 |
|
|
| 1802 |
Executive Functioning Considerations |
2018-03-02 |
|
|
| 1803 |
Screening and Assessment of FASD |
2018-03-02 |
|
|
| 1804 |
Distinguishing Primary and Secondary Disabilities of FASD |
2018-03-02 |
|
|
| 1805 |
Diagnostic Criteria |
2018-03-02 |
|
|
| 1806 |
Fetal Alcohol Spectrum Disorder (FASD) |
2018-03-02 |
|
|
| 1807 |
Fund Project |
2018-03-02 |
|
|
| 1808 |
Contributions |
2018-03-02 |
|
|
| 1809 |
Declaration |
2018-03-02 |
|
|
| 1810 |
Medical Observation |
2018-03-02 |
|
|
| 1811 |
Case Series |
2018-03-01 |
|
|
| 1812 |
Review |
2018-03-01 |
|
|
| 1813 |
DISCUSSION |
2018-02-23 |
|
|
| 1814 |
Numerical Solution of 3D Navier-Stokes Equations |
2018-02-21 |
|
|
| 1815 |
A Model of Linearized Navier-Stokes Equations |
2018-02-21 |
|
|
| 1816 |
Recommendation |
2018-02-12 |
|
|
| 1817 |
The Best Moment to Measure Amh |
2018-02-12 |
|
|
| 1818 |
Amh Variations Observed During the Natural Cycle |
2018-02-12 |
|
|
| 1819 |
The Intracycle Variations During Ovarian Stimulation for Ivf-Icsi |
2018-02-12 |
|
|
| 1820 |
Definitions |
2018-02-03 |
|
|
| 1821 |
Grant Support |
2018-02-03 |
|
|
| 1822 |
Patient Consent |
2018-02-03 |
|
|
| 1823 |
Conflicting Interests |
2018-02-03 |
|
|
| 1824 |
Details of Contributors |
2018-02-02 |
|
|
| 1825 |
Cytokine Gene Polymorphisms and Viral Infections |
2018-02-02 |
|
|
| 1826 |
Biopiles |
2018-02-01 |
|
|
| 1827 |
Bioventing |
2018-02-01 |
|
|
| 1828 |
Genetically Engineered Microorganisms (GEMS) |
2018-02-01 |
|
|
| 1829 |
Types of Bioremediation |
2018-02-01 |
|
|
| 1830 |
Microorganisms and Pollutants |
2018-02-01 |
|
|
| 1831 |
Contribution details |
2018-01-30 |
|
|
| 1832 |
Fragile X Syndrome |
2018-01-17 |
|
|
| 1833 |
Recommendations for Future Research |
2018-01-17 |
|
|
| 1834 |
Etiology of Schizophrenia and Parkinson’s |
2018-01-17 |
|
|
| 1835 |
Discussion and Future Directions |
2018-01-15 |
|
|
| 1836 |
Improving Phytase Activity by Using Organic Acids |
2018-01-15 |
|
|
| 1837 |
Phytases and Their Substrate |
2018-01-15 |
|
|
| 1838 |
Consent |
2018-01-11 |
|
|
| 1839 |
Ethical Approval |
2018-01-11 |
|
|
| 1840 |
Research Limitations |
2018-01-11 |
|
|
| 1841 |
Key Message |
2018-01-11 |
|
|
| 1842 |
Declarations |
2018-01-10 |
|
|
| 1843 |
Competing Interest |
2018-01-10 |
|
|
| 1844 |
Policy Issues |
2018-01-10 |
|
|
| 1845 |
Toxicity Assays |
2018-01-10 |
|
|
| 1846 |
Strategies for Developing Animal Models |
2018-01-10 |
|
|
| 1847 |
Natural Models |
2018-01-10 |
|
|
| 1848 |
Conflicts of Interest |
2018-01-10 |
|
|
| 1849 |
Ethical Publication Statement |
2018-01-10 |
|
|
| 1850 |
Case Study |
2018-01-10 |
|
|
| 1851 |
Future Directions of Immunohistochemistry |
2018-01-09 |
|
|
| 1852 |
Application of IHC in Histopathology |
2018-01-09 |
|
|
| 1853 |
Application of IHC in Histological Research |
2018-01-09 |
|
|
| 1854 |
Study Area |
2018-01-09 |
|
|
| 1855 |
Clinical Correlation |
2018-01-09 |
|
|
| 1856 |
Conclusion and Recommendation |
2018-01-09 |
|
|
| 1857 |
Plafond fractures, Post-traumatic osteoarthritis and ankle reconctruction |
2018-01-08 |
|
|
| 1858 |
Clinical outcome of treatment af Tibial Plafond(Pilon) Fractures |
2018-01-08 |
|
|
| 1859 |
Risk Factors for Post-Traumatic OA |
2018-01-08 |
|
|
| 1860 |
Pathophysiology Of Osteoarthritis |
2018-01-08 |
|
|
| 1861 |
Hypothesized Microbial Ecology |
2018-01-08 |
|
|
| 1862 |
New Geobiological Observations |
2018-01-08 |
|
|
| 1863 |
Chronostratigraphy |
2018-01-08 |
|
|
| 1864 |
New Rock Magnetic Measurements |
2018-01-08 |
|
|
| 1865 |
Reanalysis of the Schwartz et al. (1997) Rock Magnetic Data |
2018-01-08 |
|
|
| 1866 |
Assessing BBOR Geochemical Conditions |
2018-01-08 |
|
|
| 1867 |
Blake/Bahama Outer Ridge (BBOR) Sedimentation Processes |
2018-01-08 |
|
|
| 1868 |
Previous Field Studies |
2018-01-08 |
|
|
| 1869 |
Results and Conclusion |
2018-01-07 |
|
|
| 1870 |
Strategies of Minimizing Mortality |
2018-01-07 |
|
|
| 1871 |
Techniques |
2018-01-07 |
|
|
| 1872 |
Surgical Revascularization |
2018-01-07 |
|
|
| 1873 |
Percutaneous Mechanical Thrombectomy (PMT) |
2018-01-07 |
|
|
| 1874 |
Endovascular Treatment |
2018-01-07 |
|
|
| 1875 |
Treatment Selection |
2018-01-07 |
|
|
| 1876 |
Therapeutic Management |
2018-01-07 |
|
|
| 1877 |
Magnetic Resonance Angiography (MRA) |
2018-01-07 |
|
|
| 1878 |
CT Angiography |
2018-01-07 |
|
|
| 1879 |
Conventional Arteriography |
2018-01-07 |
|
|
| 1880 |
Duplex Ultrasound |
2018-01-07 |
|
|
| 1881 |
Further Imaging |
2018-01-07 |
|
|
| 1882 |
Assessment and Classification |
2018-01-07 |
|
|
| 1883 |
Thrombosis |
2018-01-07 |
|
|
| 1884 |
Embolism |
2018-01-07 |
|
|
| 1885 |
Result and Discussion |
2018-01-06 |
|
|
| 1886 |
Determination of Functional Properties |
2018-01-06 |
|
|
| 1887 |
Experimental Design and Modelling for Optimization |
2018-01-06 |
|
|
| 1888 |
Visual Detection |
2018-01-06 |
|
|
| 1889 |
Food Borne Pathogens |
2018-01-06 |
|
|
| 1890 |
Regression Analysis |
2018-01-06 |
|
|
| 1891 |
Correlation and Casuation Analysis |
2018-01-06 |
|
|
| 1892 |
Gastrointestinal Digestion |
2018-01-06 |
|
|
| 1893 |
PH Changes |
2018-01-06 |
|
|
| 1894 |
Drug Development |
2018-01-06 |
|
|
| 1895 |
Food Safety on Human Health |
2018-01-06 |
|
|
| 1896 |
Scope |
2018-01-06 |
|
|
| 1897 |
Non-Coding RNAs |
2018-01-06 |
|
|
| 1898 |
Radiation and Stress Inducible Genes |
2018-01-06 |
|
|
| 1899 |
Bacterial and Mitochondial Relationship |
2018-01-06 |
|
|
| 1900 |
Conclusion and Recommendations |
2018-01-06 |
|
|
| 1901 |
The Bottom Line for Biotech Entrepreneurship |
2018-01-06 |
|
|
| 1902 |
Biochemical Entrepreneurship |
2018-01-06 |
|
|
| 1903 |
Opinion |
2018-01-06 |
|
|
| 1904 |
Future Work |
2018-01-05 |
|
|
| 1905 |
Enzymic Synthesis |
2018-01-05 |
|
|
| 1906 |
Enzyme Immobilization |
2018-01-05 |
|
|
| 1907 |
Clinical Case Presentation |
2018-01-05 |
|
|
| 1908 |
Ethical Statement |
2018-01-05 |
|
|
| 1909 |
Role Of Long Non-Coding RNAs (LncRNAs) in Sci |
2018-01-05 |
|
|
| 1910 |
Role of miRNA in Sci |
2018-01-05 |
|
|
| 1911 |
Non-Coding Rna in Spinal Cord Injury |
2018-01-05 |
|
|
| 1912 |
Role of Stem Cells in Sci |
2018-01-05 |
|
|
| 1913 |
Conclusion and Outlook |
2018-01-05 |
|
|
| 1914 |
Environmental Response Mesoporous Silicon Dioxide Drug Delivery System |
2018-01-05 |
|
|
| 1915 |
Drug Delivery System |
2018-01-05 |
|
|
| 1916 |
Synthesis of Mesoporous Silica Nanoparticles |
2018-01-05 |
|
|
| 1917 |
Disclosure |
2018-01-05 |
|
|
| 1918 |
Data Recollection |
2018-01-05 |
|
|
| 1919 |
Clinical Implication |
2018-01-05 |
|
|
| 1920 |
Engineering Application: Hurricane Dynamics and Solution of 3d Navier-Stokes |
2018-01-05 |
|
|
| 1921 |
Deriving Ermakov-Type Equation for Newtonian Universe with Vortex |
2018-01-04 |
|
|
| 1922 |
Spiral Galaxy Model |
2018-01-04 |
|
|
| 1923 |
Solar System Model |
2018-01-04 |
|
|
| 1924 |
A Few Historical Notes |
2018-01-04 |
|
|
| 1925 |
Material and Methods |
2018-01-04 |
|
|
| 1926 |
Introduction- Nerves of the Pelvis |
2018-01-04 |
|
|
| 1927 |
Summary of Linkers |
2018-01-03 |
|
|
| 1928 |
Conjugation Chemistry |
2018-01-03 |
|
|
| 1929 |
Hungarian Experience |
2018-01-03 |
|
|
| 1930 |
Ethics Committees |
2018-01-03 |
|
|
| 1931 |
Phases of Drug Development |
2018-01-03 |
|
|
| 1932 |
Registration Trends of New Drugs |
2018-01-03 |
|
|
| 1933 |
Implications |
2018-01-03 |
|
|
| 1934 |
Literature Review |
2018-01-03 |
|
|
| 1935 |
Rotem platelets |
2018-01-03 |
|
|
| 1936 |
Rotem |
2018-01-03 |
|
|
| 1937 |
Teg |
2018-01-03 |
|
|
| 1938 |
Case Report 2 |
2018-01-03 |
|
|
| 1939 |
Case Report 1 |
2018-01-03 |
|
|
| 1940 |
Ethical Consideration |
2018-01-02 |
|
|
| 1941 |
Grading of the Oocyte Morphology |
2018-01-02 |
|
|
| 1942 |
Materials |
2018-01-02 |
|
|
| 1943 |
Pathophysiological Connection Between Tbi and Stroke |
2017-12-27 |
|
|
| 1944 |
Declaration of Conflicting Interests |
2017-12-27 |
|
|
| 1945 |
Informed Consent |
2017-12-18 |
|
|
| 1946 |
Ethics Committee Approval |
2017-12-18 |
|
|
| 1947 |
Source of Funding |
2017-12-18 |
|
|
| 1948 |
Trustworties |
2017-12-18 |
|
|
| 1949 |
Findings Due to Experiences of the Individuals with Stoma |
2017-12-18 |
|
|
| 1950 |
Material and Method |
2017-12-18 |
|
|
| 1951 |
Procedures |
2017-12-18 |
|
|
| 1952 |
Prospect |
2017-12-18 |
|
|
| 1953 |
Ethical standards |
2017-12-18 |
|
|
| 1954 |
Short Communication |
2017-12-17 |
|
|
| 1955 |
Learning Outcome |
2017-12-14 |
|
|
| 1956 |
Since the Intervention |
2017-12-14 |
|
|
| 1957 |
Setting up the Project |
2017-12-14 |
|
|
| 1958 |
The Project |
2017-12-14 |
|
|
| 1959 |
Literature Survey |
2017-12-14 |
|
|
| 1960 |
Study Implications |
2017-12-14 |
|
|
| 1961 |
Discussion and Recommendations |
2017-12-14 |
|
|
| 1962 |
Observational Findings |
2017-12-14 |
|
|
| 1963 |
Further Research and Perspectives |
2017-12-13 |
|
|
| 1964 |
Recommendations For Treatment |
2017-12-05 |
|
|
| 1965 |
Other Symptoms Not Yet Identified In The Spiritual Or New Age Literature |
2017-12-05 |
|
|
| 1966 |
Symptoms That Resemble New Age And Spiritual Phenomena |
2017-12-05 |
|
|
| 1967 |
Symptoms In Schizophrenia |
2017-12-05 |
|
|
| 1968 |
Measuring Phantom’s Index of Refraction |
2017-12-04 |
|
|
| 1969 |
Absorption Spectrum of AG Nanoparticles Embedded in gel Phantom |
2017-12-04 |
|
|
| 1970 |
Optical Properties of Gel Ballistic Phantom |
2017-12-04 |
|
|
| 1971 |
Theory |
2017-12-04 |
|
|
| 1972 |
Spectral Measurements |
2017-12-04 |
|
|
| 1973 |
Experiment |
2017-12-04 |
|
|
| 1974 |
How India Will Benefit From IT? |
2017-11-30 |
|
|
| 1975 |
Formulary Manual |
2017-11-30 |
|
|
| 1976 |
Preparation and Management of Hospi-tal Formulary |
2017-11-30 |
|
|
| 1977 |
Hospital Formulary System |
2017-11-30 |
|
|
| 1978 |
External funding source |
2017-11-30 |
|
|
| 1979 |
Strength of the Study |
2017-11-30 |
|
|
| 1980 |
Pre-Incubation of Mitochondria in the VLC Fraction |
2017-11-30 |
|
|
| 1981 |
Mitochondrial Swelling Assay |
2017-11-30 |
|
|
| 1982 |
Isolation of Rat Liver Mitochondria |
2017-11-30 |
|
|
| 1983 |
Vacuum Liquid Chromatography Purification Procedure |
2017-11-30 |
|
|
| 1984 |
Tissue Hormonal Evaluation |
2017-11-30 |
|
|
| 1985 |
Histopathological Evaluation |
2017-11-30 |
|
|
| 1986 |
Molecular Evaluation |
2017-11-30 |
|
|
| 1987 |
Guarantor |
2017-11-30 |
|
|
| 1988 |
Treatment Schedule |
2017-11-30 |
|
|
| 1989 |
Objectives |
2017-11-30 |
|
|
| 1990 |
Observations |
2017-11-27 |
|
|
| 1991 |
Patients and Observations |
2017-11-25 |
|
|
| 1992 |
Discussion on Internship |
2017-11-25 |
|
|
| 1993 |
Letter to the Editor |
2017-11-25 |
|
|
| 1994 |
Dimensional characteristics of the knee among Asian populations |
2017-11-25 |
|
|
| 1995 |
According to their occurrence |
2017-11-24 |
|
|
| 1996 |
Mesiodens |
2017-11-24 |
|
|
| 1997 |
Theories of Dentigerous cyst formation |
2017-11-24 |
|
|
| 1998 |
Method |
2017-11-24 |
|
|
| 1999 |
Authorship |
2017-11-23 |
|
|
| 2000 |
Author Disclosure Statement |
2017-11-23 |
|
|
| 2001 |
Clinical Image |
2017-11-16 |
|
|
| 2002 |
Cardiovascular Treatment and Cancer Risk |
2017-11-16 |
|
|
| 2003 |
Cardio-Oncology is Crucial |
2017-11-16 |
|
|
| 2004 |
Detecting Cancers |
2017-11-16 |
|
|
| 2005 |
Cardiac Effects of Cancer Therapies |
2017-11-16 |
|
|
| 2006 |
Cardio-Oncology – An Overview |
2017-11-16 |
|
|
| 2007 |
Methods of Preparation |
2017-11-16 |
|
|
| 2008 |
Homeostasis |
2017-11-14 |
|
|
| 2009 |
Concluding Remarks |
2017-11-03 |
|
|
| 2010 |
Connectomics |
2017-11-03 |
|
|
| 2011 |
Diffusion Magnetic Resonance Imaging |
2017-11-03 |
|
|
| 2012 |
Resting-State Functional Brain Imaging |
2017-11-03 |
|
|
| 2013 |
Functional Brain Imaging |
2017-11-03 |
|
|
| 2014 |
Commentary |
2017-11-03 |
|
|
| 2015 |
Data and Materials |
2017-10-17 |
|
|
| 2016 |
Design of Shape Memory Hybrid |
2017-10-17 |
|
|
| 2017 |
Experimental |
2017-10-17 |
|
|
| 2018 |
Description |
2017-10-17 |
|
|
| 2019 |
Strength and Limitation of the Study |
2017-10-15 |
|
|
| 2020 |
Source of funding statement |
2017-10-13 |
|
|
| 2021 |
Authors Contributions |
2017-10-13 |
|
|
| 2022 |
Rationale |
2017-10-13 |
|
|
| 2023 |
Letter to Editor |
2017-10-12 |
|
|
| 2024 |
Estimation of lipid profile levels |
2017-10-12 |
|
|
| 2025 |
Limitation |
2017-10-12 |
|
|
| 2026 |
Demographic Information of Poisonous Patients |
2017-10-12 |
|
|
| 2027 |
Financial Support |
2017-10-12 |
|
|
| 2028 |
Study limitations |
2017-10-12 |
|
|
| 2029 |
African and Global Bioethics: Facing the Future |
2017-10-07 |
|
|
| 2030 |
Bioethics Principles in African Construct |
2017-10-07 |
|
|
| 2031 |
Method of Collection of Data |
2017-10-07 |
|
|
| 2032 |
Acceptance of Legislation Against FGM |
2017-10-07 |
|
|
| 2033 |
Awareness of Campaign Against Female Genital Mutilation |
2017-10-07 |
|
|
| 2034 |
The steps of fuzzy AHP |
2017-10-07 |
|
|
| 2035 |
Fuzzy analytic hierarchy process |
2017-10-07 |
|
|
| 2036 |
Observation |
2017-10-07 |
|
|
| 2037 |
Histopathological Examination |
2017-10-07 |
|
|
| 2038 |
Control |
2017-10-07 |
|
|
| 2039 |
Instruments |
2017-10-06 |
|
|
| 2040 |
Histopathology Result |
2017-10-06 |
|
|
| 2041 |
Findings |
2017-10-06 |
|
|
| 2042 |
Ethical aspects |
2017-10-06 |
|
|
| 2043 |
Results all OR or RR must be Accompanied by the 95% CI |
2017-10-05 |
|
|
| 2044 |
Trial Registration Number |
2017-10-05 |
|
|
| 2045 |
Strengths |
2017-10-05 |
|
|
| 2046 |
Methods and Analysis |
2017-10-05 |
|
|
| 2047 |
Complications and Risks Following Surgery |
2017-10-05 |
|
|
| 2048 |
Complications and Risks Following Surgery |
2017-10-05 |
|
|
| 2049 |
Indications for Mandibular Third Molar Extraction |
2017-10-05 |
|
|
| 2050 |
Indications for Mandibular Third Molar Extraction |
2017-10-05 |
|
|
| 2051 |
Management of Impacted Tooth |
2017-10-05 |
|
|
| 2052 |
Assessment of Third Molar |
2017-10-05 |
|
|
| 2053 |
Late Crowding in Lower Incisors |
2017-10-05 |
|
|
| 2054 |
Case History |
2017-10-05 |
|
|
| 2055 |
Pathological Changes Associated with Impacted Third Molars |
2017-10-05 |
|
|
| 2056 |
Classification |
2017-10-05 |
|
|
| 2057 |
Causes of Impacted Teeth |
2017-10-05 |
|
|
| 2058 |
Source of Support |
2017-10-05 |
|
|
| 2059 |
Surgical Procedure |
2017-10-05 |
|
|
| 2060 |
Challenges |
2017-10-05 |
|
|
| 2061 |
Technical Note |
2017-10-05 |
|
|
| 2062 |
Administrative skills |
2017-10-05 |
|
|
| 2063 |
Skill acquisition |
2017-10-05 |
|
|
| 2064 |
Study design |
2017-10-05 |
|
|
| 2065 |
Study population |
2017-10-05 |
|
|
| 2066 |
Detection of carbapenemase production |
2017-10-05 |
|
|
| 2067 |
Conclusion/Recommendation |
2017-10-05 |
|
|
| 2068 |
Argument Based on Socio-Cultural Values |
2017-10-05 |
|
|
| 2069 |
Design |
2017-10-05 |
|
|
| 2070 |
Strengths and Limitations |
2017-10-05 |
|
|
| 2071 |
Imaging and Management |
2017-10-05 |
|
|
| 2072 |
Conclusions and Recommendation |
2017-10-05 |
|
|
| 2073 |
Limitation to the Study |
2017-10-05 |
|
|
| 2074 |
Methods for the Case Series |
2017-10-05 |
|
|
| 2075 |
Artemisinins Toxicity |
2017-10-05 |
|
|
| 2076 |
Resistance to Artemisinins |
2017-10-05 |
|
|
| 2077 |
Artemisinins in Combination Chemotherapy for Cancer |
2017-10-05 |
|
|
| 2078 |
Artemisinins |
2017-10-05 |
|
|
| 2079 |
Methods of Literature Search |
2017-10-05 |
|
|
| 2080 |
Observations and Results |
2017-10-05 |
|
|
| 2081 |
Clinical Presentation |
2017-10-05 |
|
|
| 2082 |
Method of Registry Compilation |
2017-10-04 |
|
|
| 2083 |
Results and Statistical Analysis |
2017-10-04 |
|
|
| 2084 |
Statistical Method |
2017-10-04 |
|
|
| 2085 |
Procedure |
2017-10-04 |
|
|
| 2086 |
Conclusion and Final Considerations |
2017-10-04 |
|
|
| 2087 |
Objective |
2017-10-04 |
|
|
| 2088 |
Oral Health Care Reforms in Developed Countries |
2017-10-04 |
|
|
| 2089 |
Dental Insurance Policy |
2017-10-04 |
|
|
| 2090 |
Mobile and Portable Dental Services |
2017-10-04 |
|
|
| 2091 |
Public-private Partnership |
2017-10-04 |
|
|
| 2092 |
Street Dentistry: Tackling Quackery |
2017-10-04 |
|
|
| 2093 |
Strategy to Improve Oral Health of Children |
2017-10-04 |
|
|
| 2094 |
Improving Geriatric Oral Health |
2017-10-04 |
|
|
| 2095 |
Loss of Working Hours |
2017-10-04 |
|
|
| 2096 |
Oral Health Care Expenditure |
2017-10-04 |
|
|
| 2097 |
Barriers in Oral Health Promotion |
2017-10-04 |
|
|
| 2098 |
Oral Health Burden in India |
2017-10-04 |
|
|
| 2099 |
Case Reports |
2017-10-04 |
|
|
| 2100 |
What Can Physicians Do? The Public Health Approach |
2017-10-04 |
|
|
| 2101 |
Response by the Nigerian Government |
2017-10-04 |
|
|
| 2102 |
Why Does Road Traffic Accidents Deserve the Government’s Time, Energy and Focus? |
2017-10-04 |
|
|
| 2103 |
Competing Interests |
2017-10-04 |
|
|
| 2104 |
Image Article |
2017-09-25 |
|
|
| 2105 |
Corrections Made |
2017-09-25 |
|
|
| 2106 |
Article Corrected |
2017-09-25 |
|
|
| 2107 |
Financial support and sponsorship |
2017-09-22 |
|
|
| 2108 |
Method of Literature Search |
2017-09-22 |
|
|
| 2109 |
Do not Forget to Negotiate |
2017-09-22 |
|
|
| 2110 |
Involve the Team in Budget Planning |
2017-09-22 |
|
|
| 2111 |
Beware Relying too Much on the Previous Cycle’s Activity and Budget |
2017-09-22 |
|
|
| 2112 |
Consider What Your Budget Cycle Should be |
2017-09-22 |
|
|
| 2113 |
Evaluate the Outcomes, Learn from Them,and Start Planning Again |
2017-09-22 |
|
|
| 2114 |
Monitor Adherence to the Planned Budget |
2017-09-22 |
|
|
| 2115 |
Communicate the Budget Plan to the Team |
2017-09-22 |
|
|
| 2116 |
Get Involved in Budget Planning |
2017-09-22 |
|
|
| 2117 |
Think About Your Department’s Goals and Strategy |
2017-09-22 |
|
|
| 2118 |
Addendum |
2017-09-21 |
|
|
| 2119 |
Clinical Significance |
2017-09-21 |
|
|
| 2120 |
CONCLUSION |
2017-09-21 |
|
|
| 2121 |
Case |
2017-09-17 |
|
|
| 2122 |
The Empirical Study and Results |
2017-09-17 |
|
|
| 2123 |
Background and A Brief Overview of The Study |
2017-09-17 |
|
|
| 2124 |
Cardiovascular Safety |
2017-09-14 |
|
|
| 2125 |
Phase III Studies |
2017-09-14 |
|
|
| 2126 |
Efficacy in Patients with ED |
2017-09-14 |
|
|
| 2127 |
Drug Interactions |
2017-09-14 |
|
|
| 2128 |
Clinical Pharmacokinetics and Metabolism |
2017-09-14 |
|
|
| 2129 |
Implications for Future Studies |
2017-09-14 |
|
|
| 2130 |
Risk factors for GenitaL Chlamydia |
2017-09-14 |
|
|
| 2131 |
Occurrence of Genital Chlamydia |
2017-09-14 |
|
|
| 2132 |
Surgery |
2017-09-14 |
|
|
| 2133 |
Other Techniques |
2017-09-14 |
|
|
| 2134 |
Nerve Stimulation |
2017-09-14 |
|
|
| 2135 |
Bladder Hydrodistension |
2017-09-14 |
|
|
| 2136 |
Intravesical Agents |
2017-09-14 |
|
|
| 2137 |
Oral Medication |
2017-09-14 |
|
|
| 2138 |
Lifestyle |
2017-09-14 |
|
|
| 2139 |
Chronic Pelvic Pain Syndrome: Similarity To IC |
2017-09-14 |
|
|
| 2140 |
Diagnostic Tools |
2017-09-14 |
|
|
| 2141 |
Etiology and Pathogenesis |
2017-09-14 |
|
|
| 2142 |
Epidemiology and History |
2017-09-14 |
|
|
| 2143 |
The Adolescent |
2017-09-14 |
|
|
| 2144 |
Puberty |
2017-09-14 |
|
|
| 2145 |
Common Gynecological Disorders of the Prepubertal Child |
2017-09-14 |
|
|
| 2146 |
Examination of the Prepubertal Child |
2017-09-14 |
|
|
| 2147 |
Treatment Strategies for Professional Sexual Misconduct |
2017-09-14 |
|
|
| 2148 |
Key Points |
2017-09-13 |
|
|
| 2149 |
Treatment and follow-up of Neonatal Hsv Infection |
2017-09-13 |
|
|
| 2150 |
Laboratory Diagnosis |
2017-09-13 |
|
|
| 2151 |
Management of the Exposed Asymptomatic Newborn |
2017-09-13 |
|
|
| 2152 |
Prevention of Neonatal Hsv Infection |
2017-09-13 |
|
|
| 2153 |
Features of Neonatal Hsv Infections |
2017-09-13 |
|
|
| 2154 |
Bibliography |
2017-09-13 |
|
|
| 2155 |
Prevention and Treatment of Male Osteoporosis |
2017-09-13 |
|
|
| 2156 |
Bone Mineral Density, and Risk Factors for Osteoporosis and Fracture |
2017-09-13 |
|
|
| 2157 |
Etiology and Pathogenesis |
2017-09-13 |
|
|
| 2158 |
Epidemiology of Osteoporosis and Fractures in men |
2017-09-13 |
|
|
| 2159 |
Significance to Clinicians |
2017-09-13 |
|
|
| 2160 |
Congenital Anomalies in IVF and ICSI |
2017-09-13 |
|
|
| 2161 |
Chromosomal Abnormalities After IVF and ICSI |
2017-09-13 |
|
|
| 2162 |
Spontaneous Abortion Rate with IVF and ICSI |
2017-09-13 |
|
|
| 2163 |
Transmission of Existing Genetic Abnormalities Through Assisted Reproduction |
2017-09-13 |
|
|
| 2164 |
What are These Conditions? |
2017-09-13 |
|
|
| 2165 |
Are They Really the Same Condition? |
2017-09-13 |
|
|
| 2166 |
Complications and Limitations of Art |
2017-09-13 |
|
|
| 2167 |
Results of Assisted Reproduction |
2017-09-13 |
|
|
| 2168 |
New Developments in Art |
2017-09-13 |
|
|
| 2169 |
Oocyte Donation |
2017-09-13 |
|
|
| 2170 |
Cryopreservation in Art |
2017-09-13 |
|
|
| 2171 |
Prostate Biopsy |
2017-09-13 |
|
|
| 2172 |
Serum Markers and Digital Rectal Examination |
2017-09-13 |
|
|
| 2173 |
Prostatic Carcinogenesis and Hormones |
2017-09-13 |
|
|
| 2174 |
Results of Treatment |
2017-09-13 |
|
|
| 2175 |
Therapeutic Options |
2017-09-13 |
|
|
| 2176 |
Androgen Deficiency in the aging male and Sex: Clicnical Picture |
2017-09-13 |
|
|
| 2177 |
Androgen Deficiency in the aging male and Sex: Clicnical Picture |
2017-09-13 |
|
|
| 2178 |
Vasectomy Reversal |
2017-09-13 |
|
|
| 2179 |
Vasectomy |
2017-09-13 |
|
|
| 2180 |
Empirical Therapy |
2017-09-13 |
|
|
| 2181 |
Specific Pharmacological Therapy |
2017-09-13 |
|
|
| 2182 |
Specific surgical Therapy |
2017-09-13 |
|
|
| 2183 |
Management |
2017-09-13 |
|
|
| 2184 |
Laboratory Tests |
2017-09-13 |
|
|
| 2185 |
Testosterone is Not Just Sexual |
2017-09-13 |
|
|
| 2186 |
Evaluation |
2017-09-13 |
|
|
| 2187 |
Case Presentations |
2017-09-13 |
|
|
| 2188 |
Length of Treatment |
2017-09-13 |
|
|
| 2189 |
Obstructive Oligospermia |
2017-09-13 |
|
|
| 2190 |
Depression and Andropause |
2017-09-13 |
|
|
| 2191 |
Chemotherapy, Radiation and Gonadotoxins |
2017-09-13 |
|
|
| 2192 |
Fever and Oligoasthenospermia |
2017-09-13 |
|
|
| 2193 |
Antisperm Antibodies |
2017-09-13 |
|
|
| 2194 |
Sexual Dysfunction in Depression |
2017-09-13 |
|
|
| 2195 |
Pyospermia |
2017-09-13 |
|
|
| 2196 |
Major Depression |
2017-09-13 |
|
|
| 2197 |
Genetic Disorders |
2017-09-13 |
|
|
| 2198 |
Cryptorchidism |
2017-09-13 |
|
|
| 2199 |
Effect of Decreased Testosterone Levels |
2017-09-13 |
|
|
| 2200 |
Varicocele |
2017-09-13 |
|
|
| 2201 |
Testosterone Physiology |
2017-09-13 |
|
|
| 2202 |
Endocrinological Abnormalities |
2017-09-13 |
|
|
| 2203 |
Prevention and Treatment |
2017-09-13 |
|
|
| 2204 |
Mechanisms of SCD |
2017-09-13 |
|
|
| 2205 |
CAD and Cardiomyopathies |
2017-09-13 |
|
|
| 2206 |
Patient Preference |
2017-09-13 |
|
|
| 2207 |
Efficacy |
2017-09-13 |
|
|
| 2208 |
Outcome Measures |
2017-09-13 |
|
|
| 2209 |
Pharmacology of Tadalafil |
2017-09-13 |
|
|
| 2210 |
Safety |
2017-09-13 |
|
|
| 2211 |
Is Reliability Important |
2017-09-13 |
|
|
| 2212 |
Vardenafil Works Rapidly |
2017-09-13 |
|
|
| 2213 |
Therapeutic Efficacy |
2017-09-13 |
|
|
| 2214 |
Experimental Setup |
2017-09-13 |
|
|
| 2215 |
Nuclear Licensing Regimes |
2017-09-13 |
|
|
| 2216 |
Independence of the Regulatory Authority |
2017-09-13 |
|
|
| 2217 |
Target Organs |
2017-09-12 |
|
|
| 2218 |
Testosterone |
2017-09-12 |
|
|
| 2219 |
Testes |
2017-09-12 |
|
|
| 2220 |
Hypothalamus and Pituitary Function |
2017-09-12 |
|
|
| 2221 |
Testosterone and Stress – The Cortex |
2017-09-12 |
|
|
| 2222 |
The High Testosterone Male |
2017-09-12 |
|
|
| 2223 |
Androgen Profile |
2017-09-12 |
|
|
| 2224 |
Luteinizing Hormone |
2017-09-12 |
|
|
| 2225 |
Prolactin |
2017-09-12 |
|
|
| 2226 |
Insulinemia |
2017-09-12 |
|
|
| 2227 |
Thyroid Profile |
2017-09-12 |
|
|
| 2228 |
Basic Biochemical Profile |
2017-09-12 |
|
|
| 2229 |
Symptoms of Andropause |
2017-09-12 |
|
|
| 2230 |
Clinical Diagnosis of Andropause |
2017-09-12 |
|
|
| 2231 |
Screening for Andropause |
2017-09-12 |
|
|
| 2232 |
Definition |
2017-09-12 |
|
|
| 2233 |
Varicocelectomy |
2017-09-12 |
|
|
| 2234 |
Diagnosis |
2017-09-12 |
|
|
| 2235 |
Testicular atrophy |
2017-09-12 |
|
|
| 2236 |
Pathophysiology |
2017-09-12 |
|
|
| 2237 |
Mechanisms |
2017-09-12 |
|
|
| 2238 |
Etiology |
2017-09-12 |
|
|
| 2239 |
Incidence |
2017-09-12 |
|
|
| 2240 |
Assisted Reproduction for Obstructive Azoospermia |
2017-09-11 |
|
|
| 2241 |
Evaluation for Obstructive Azoospermia |
2017-09-11 |
|
|
| 2242 |
Obstructive Azoospermia |
2017-09-11 |
|
|
| 2243 |
Assisted Reproduction for Nonobstructive Azoospermia |
2017-09-11 |
|
|
| 2244 |
Treatments for Nonobstructive Azoospermia |
2017-09-11 |
|
|
| 2245 |
Nonobstructive Azoospermia |
2017-09-11 |
|
|
| 2246 |
Investigations |
2017-09-11 |
|
|
| 2247 |
Specialized Tests |
2017-09-11 |
|
|
| 2248 |
Ultrasound Evaluation |
2017-09-11 |
|
|
| 2249 |
Hormonal Studies |
2017-09-11 |
|
|
| 2250 |
Basic Tests |
2017-09-11 |
|
|
| 2251 |
Physical Examinations |
2017-09-11 |
|
|
| 2252 |
Clinical History |
2017-09-11 |
|
|
| 2253 |
Clinical Evaluation – Anotomical and Phyiological Considerations |
2017-09-11 |
|
|
| 2254 |
Apomorphine: A centrally Acting Oral Ed therapy |
2017-09-11 |
|
|
| 2255 |
New Pde-5 Inhibitors |
2017-09-11 |
|
|
| 2256 |
Treatment |
2017-09-11 |
|
|
| 2257 |
Prevention |
2017-09-11 |
|
|
| 2258 |
Clinical Investigations |
2017-09-11 |
|
|
| 2259 |
Neurovascular anatomy and Vulnerability |
2017-09-11 |
|
|
| 2260 |
surveys |
2017-09-11 |
|
|
| 2261 |
Case Studies |
2017-09-11 |
|
|
| 2262 |
Managing Ejaculatory and Orgasmic Disorders |
2017-09-11 |
|
|
| 2263 |
Clinical Definitions of Ejaculatory and Orgasmic Concerns |
2017-09-11 |
|
|
| 2264 |
Orgasm and Ejaculation:What is the difference? |
2017-09-11 |
|
|
| 2265 |
Recommendations |
2017-09-11 |
|
|
| 2266 |
Making the Diagnosis |
2017-09-11 |
|
|
| 2267 |
The Step-Wise Approach to the Patient |
2017-09-11 |
|
|
| 2268 |
Global Management Objectives |
2017-09-11 |
|
|
| 2269 |
Summary Concepts |
2017-09-11 |
|
|
| 2270 |
Sexuality Education For The Adolescent |
2017-09-11 |
|
|
| 2271 |
Sexuality Education For The Child In Early Puberty |
2017-09-11 |
|
|
| 2272 |
Sexuality Development In Prepubertal Children |
2017-09-11 |
|
|
| 2273 |
Data and Methods |
2017-09-11 |
|
|
| 2274 |
Future Challenges |
2017-09-11 |
|
|
| 2275 |
Genital Chlamydial Infection |
2017-09-11 |
|
|
| 2276 |
Syphilis |
2017-09-11 |
|
|
| 2277 |
Gonorrhea |
2017-09-11 |
|
|
| 2278 |
Hormonal Regimen After Srs |
2017-09-11 |
|
|
| 2279 |
Outcome of Low Dose Estrogen Administration, Testosterone Suppression and Antagonism |
2017-09-11 |
|
|
| 2280 |
Individualization of Estrogen Administration |
2017-09-11 |
|
|
| 2281 |
Author’s Contribution |
2017-09-11 |
|
|
| 2282 |
Additional Potential Risks of Estrogen Administration |
2017-09-11 |
|
|
| 2283 |
Sexual Behaviour And Club Drugs |
2017-09-11 |
|
|
| 2284 |
Authors’ Contribution |
2017-09-11 |
|
|
| 2285 |
Ketamine |
2017-09-11 |
|
|
| 2286 |
Estrogen Administration and Cardiovascular Risk |
2017-09-11 |
|
|
| 2287 |
Methamphetamine |
2017-09-11 |
|
|
| 2288 |
Estrogen Administration and Cardiovascular Protection |
2017-09-11 |
|
|
| 2289 |
Feminization with Physiological Estrogen |
2017-09-11 |
|
|
| 2290 |
GHB |
2017-09-11 |
|
|
| 2291 |
LH Suppression |
2017-09-11 |
|
|
| 2292 |
MDMA |
2017-09-11 |
|
|
| 2293 |
Model Hormonal Regimen |
2017-09-11 |
|
|
| 2294 |
Drugs Used in Hormonal Treatment for Male to Female Gid |
2017-09-11 |
|
|
| 2295 |
Nursing Perspectives on Sexual Health |
2017-09-11 |
|
|
| 2296 |
FADS |
2017-09-11 |
|
|
| 2297 |
Treatment Strategies |
2017-09-11 |
|
|
| 2298 |
Diagnostic Approach |
2017-09-11 |
|
|
| 2299 |
The Four Causes Of Female Sexual Dysfunction |
2017-09-11 |
|
|
| 2300 |
Anatomy And Physiology Of The Female Sexual Response |
2017-09-11 |
|
|
| 2301 |
Prevalence |
2017-09-11 |
|
|
| 2302 |
Definition Of Female Sexual Dysfunction |
2017-09-11 |
|
|
| 2303 |
Research Design and Methods |
2017-09-11 |
|
|
| 2304 |
Review of Previous Studies |
2017-09-11 |
|
|
| 2305 |
The Application of Acupuncture Research in Metabo Nomics |
2017-09-11 |
|
|
| 2306 |
Metabo Nomics Research Methods |
2017-09-11 |
|
|
| 2307 |
Definition of Metabo Nomics |
2017-09-11 |
|
|
| 2308 |
Future Perspectives |
2017-09-11 |
|
|
| 2309 |
Tissue Engineering using 3D Bioprinting |
2017-09-11 |
|
|
| 2310 |
Material Factors |
2017-09-11 |
|
|
| 2311 |
3D Bioprinting |
2017-09-11 |
|
|
| 2312 |
Limitations of Therapeutic Stem Cell Use |
2017-09-11 |
|
|
| 2313 |
Stem Cells |
2017-09-11 |
|
|
| 2314 |
Statement of Competing Interests |
2017-09-11 |
|
|
| 2315 |
Limitations of our study and future research |
2017-09-11 |
|
|
| 2316 |
Existing Problems and Prospects in Research of Metabolomics in TCM |
2017-09-11 |
|
|
| 2317 |
Metabonomic Research on Mechanisms of Single Chinese Medicine |
2017-09-11 |
|
|
| 2318 |
Metabonomic Study of the Pharmacodynamic Material basis of Single Herbs |
2017-09-11 |
|
|
| 2319 |
Research Content and Process of Metabolomics |
2017-09-11 |
|
|
| 2320 |
Foundation Support |
2017-09-11 |
|
|
| 2321 |
Possible Mechanisms |
2017-09-10 |
|
|
| 2322 |
Cardiac Tolerance to Hypoxia in Poikilotherms |
2017-09-10 |
|
|
| 2323 |
Determinants of the Development of Compact Musculature with Vascular Supply |
2017-09-10 |
|
|
| 2324 |
Comparative Aspects of the Myocardial Structure/blood Supply Relationship |
2017-09-10 |
|
|
| 2325 |
Clinical Trials Demonstrating the Cardioprotective Effects of ALA |
2017-09-10 |
|
|
| 2326 |
Animal Research Demonstrating the Cardioprotective Effects of ALA |
2017-09-10 |
|
|
| 2327 |
Absorption Characteristics and Bioavailability of ALA |
2017-09-10 |
|
|
| 2328 |
Omega-3 Fatty Acids and CVD |
2017-09-10 |
|
|
| 2329 |
Omega-3 Fatty Acid Structure and Metabolism |
2017-09-10 |
|
|
| 2330 |
The Role of Fibre and Omega-3 Fatty Acids |
2017-09-10 |
|
|
| 2331 |
Functional Foods for the Prevention and Treatment of Cardiovascular Disease |
2017-09-10 |
|
|
| 2332 |
Multidisciplinary Support |
2017-09-10 |
|
|
| 2333 |
Use of Topical Adjuncts for Hemostasis |
2017-09-10 |
|
|
| 2334 |
Alteration of Cooling/Neuroprotective Strategies to Optimize Effects on the Coagulation Cascade |
2017-09-10 |
|
|
| 2335 |
Miniaturized Cpb |
2017-09-10 |
|
|
| 2336 |
Modification in Cpb Circuit and Prime Composition |
2017-09-10 |
|
|
| 2337 |
Autologous Transfusion |
2017-09-10 |
|
|
| 2338 |
Desmopressin |
2017-09-10 |
|
|
| 2339 |
Synthetic Lysine Analogues |
2017-09-10 |
|
|
| 2340 |
Fibrinogen |
2017-09-10 |
|
|
| 2341 |
Restrictive Transfusion Therapy |
2017-09-10 |
|
|
| 2342 |
Pharmacotherapy to Increase Blood Volume and Reduce Blood Loss |
2017-09-10 |
|
|
| 2343 |
Sources Of Funding |
2017-09-10 |
|
|
| 2344 |
Gene Delivery systems |
2017-09-09 |
|
|
| 2345 |
Therapeutic Gene targets |
2017-09-09 |
|
|
| 2346 |
Evolution of antirestenosis therapy |
2017-09-09 |
|
|
| 2347 |
Angiographic Follow-Up |
2017-09-09 |
|
|
| 2348 |
Two-Stent Versus Conventional Single-Stent Strategy |
2017-09-09 |
|
|
| 2349 |
Assessing The Severity Of LMCA Obstruction |
2017-09-09 |
|
|
| 2350 |
Risk Stratification |
2017-09-09 |
|
|
| 2351 |
Revascularization Of LMCA Stenosis |
2017-09-09 |
|
|
| 2352 |
Anatomy Of the LMCA |
2017-09-09 |
|
|
| 2353 |
Funding Sources |
2017-09-09 |
|
|
| 2354 |
Clinical aspects of ECM remodelling |
2017-09-09 |
|
|
| 2355 |
Changes in ECM composition as a consequence of myocardial ischemia |
2017-09-09 |
|
|
| 2356 |
The inflammatory response and changes in the ECM |
2017-09-09 |
|
|
| 2357 |
Myofibroblast activity and ECM changes during the course of CHF |
2017-09-09 |
|
|
| 2358 |
Composition and function of the ecm and the role of myofibroblasts in the myocardium |
2017-09-09 |
|
|
| 2359 |
Pathophysiology of myocardial remodelling in CHF |
2017-09-09 |
|
|
| 2360 |
Summary and Conclusions |
2017-09-09 |
|
|
| 2361 |
Herbal Therapies for ED |
2017-09-09 |
|
|
| 2362 |
Contraindications of PDE-5 inhibitors and adverse reactions |
2017-09-09 |
|
|
| 2363 |
Current Therapy for ED |
2017-09-09 |
|
|
| 2364 |
Pathophysiology of ED and Priapism |
2017-09-09 |
|
|
| 2365 |
Evidence-based Inotrope use in Different Cardiovascular scenarios |
2017-09-09 |
|
|
| 2366 |
Adverse Reactions to inotropres anD Vasopressors |
2017-09-09 |
|
|
| 2367 |
New Inotropic Agents and future Directions |
2017-09-09 |
|
|
| 2368 |
Calcium-sensitizinG agents |
2017-09-08 |
|
|
| 2369 |
Vasopressin |
2017-09-08 |
|
|
| 2370 |
Phosphodiesterase Inhibitors |
2017-09-08 |
|
|
| 2371 |
Catecholamines |
2017-09-08 |
|
|
| 2372 |
Contributorship |
2017-09-08 |
|
|
| 2373 |
Highlights |
2017-09-08 |
|
|
| 2374 |
Currently Used Techniques for the Evaluat ion of Heart Involvement in MD ECG |
2017-09-08 |
|
|
| 2375 |
The Future of Research on Nucleocytoplasmic Trafficking |
2017-09-08 |
|
|
| 2376 |
Ran and Nuclear Transport |
2017-09-08 |
|
|
| 2377 |
Ran and Nuclear Transport |
2017-09-08 |
|
|
| 2378 |
Nuclear Transport Receptors |
2017-09-08 |
|
|
| 2379 |
Nuclear Transport Signal Sequences |
2017-09-08 |
|
|
| 2380 |
Models of Transport |
2017-09-08 |
|
|
| 2381 |
The NPC |
2017-09-08 |
|
|
| 2382 |
Nucleocytoplasmic Trafficking |
2017-09-08 |
|
|
| 2383 |
Funding |
2017-09-07 |
|
|
| 2384 |
Percuta Neous Lv Support Devices |
2017-09-07 |
|
|
| 2385 |
Intra-Aortic Balloon Pump |
2017-09-07 |
|
|
| 2386 |
Left Ventricle Unloading |
2017-09-07 |
|
|
| 2387 |
Left Ventricular Overload During Va-Ecmo Therapy |
2017-09-07 |
|
|
| 2388 |
Clinical Indications for Va-Ecmo |
2017-09-07 |
|
|
| 2389 |
Methodology |
2017-09-07 |
|
|
| 2390 |
Conclusion and Limitations |
2017-09-07 |
|
|
| 2391 |
Patellar Sleeve Injuries |
2017-09-07 |
|
|
| 2392 |
Apophyseal Avulsions |
2017-09-07 |
|
|
| 2393 |
Transitional Ankle Injuries |
2017-09-07 |
|
|
| 2394 |
Tibia Tubercle Fractures |
2017-09-07 |
|
|
| 2395 |
Pre-Fusion |
2017-09-07 |
|
|
| 2396 |
Medial Epicondyle Fractures |
2017-09-07 |
|
|
| 2397 |
Ossification |
2017-09-07 |
|
|
| 2398 |
Femoral Physeal Separation |
2017-09-07 |
|
|
| 2399 |
Distal Humeral Physeal Separation |
2017-09-07 |
|
|
| 2400 |
Pre-Ossification |
2017-09-07 |
|
|
| 2401 |
General Considerations |
2017-09-07 |
|
|
| 2402 |
Compliance with Ethical Standards |
2017-09-07 |
|
|
| 2403 |
Patients and Methods |
2017-09-07 |
|
|
| 2404 |
Applying the Algorithm |
2017-09-07 |
|
|
| 2405 |
Experimental Procedure |
2017-09-06 |
|
|
| 2406 |
Background |
2017-09-06 |
|
|
| 2407 |
Results and Discussion |
2017-09-06 |
|
|
| 2408 |
Animations |
2017-09-06 |
|
|
| 2409 |
Operative Technique |
2017-09-06 |
|
|
| 2410 |
New Trends in “Treatment” |
2017-09-06 |
|
|
| 2411 |
New Trends in “Diagnosis” |
2017-09-06 |
|
|
| 2412 |
Cardiac Injury Leads to Fibrosis |
2017-09-06 |
|
|
| 2413 |
Oxidative Stress and Neurohormonal Activation Cause Ca2+ Transport Dysfunction |
2017-09-06 |
|
|
| 2414 |
ROS and Cardiac Hypertrophy Signalling |
2017-09-06 |
|
|
| 2415 |
Oxidative Stress as a Major Event in Cardiac Remodelling |
2017-09-06 |
|
|
| 2416 |
Summary |
2017-09-06 |
|
|
| 2417 |
Reversing Subcellular Remodelling |
2017-09-06 |
|
|
| 2418 |
Deiodinase 3 and Intracellular Thyroid Hormone Signalling |
2017-09-06 |
|
|
| 2419 |
Subcellular Remodelling |
2017-09-06 |
|
|
| 2420 |
Possible Etiology |
2017-09-06 |
|
|
| 2421 |
Discussion and Conclusion |
2017-09-06 |
|
|
| 2422 |
Editorial |
2017-09-06 |
|
|
| 2423 |
Conflict of Interest Statement |
2017-09-06 |
|
|
| 2424 |
Acknowledgements |
2017-09-06 |
|
|
| 2425 |
Case 3 |
2017-09-05 |
|
|
| 2426 |
Case 2 |
2017-09-05 |
|
|
| 2427 |
Case 1 |
2017-09-05 |
|
|
| 2428 |
Case Presentation |
2017-09-05 |
|
|
| 2429 |
MRI Processing |
2017-09-05 |
|
|
| 2430 |
Skeletal Muscle Diseases Commonly Associated with Cardiac Involvement |
2017-09-01 |
|
|
| 2431 |
Declaration of Conflict of Interest |
2017-08-31 |
|
|
| 2432 |
Hepatitis E virus Transmission |
2017-08-31 |
|
|
| 2433 |
Development |
2017-08-31 |
|
|
| 2434 |
Evidence acquisition |
2017-08-31 |
|
|
| 2435 |
Aims and Objectives |
2017-08-31 |
|
|
| 2436 |
Data analysis |
2017-08-30 |
|
|
| 2437 |
Subjects and Methods |
2017-08-30 |
|
|
| 2438 |
Author Contribution |
2017-08-30 |
|
|
| 2439 |
Aim |
2017-08-30 |
|
|
| 2440 |
Methods |
2017-08-29 |
|
|
| 2441 |
Limitations of the Study |
2017-08-17 |
|
|
| 2442 |
Statistical Analysis |
2017-08-17 |
|
|
| 2443 |
Ethical Disclosures |
2017-08-16 |
|
|
| 2444 |
Case Presentation |
2017-08-16 |
|
|
| 2445 |
No heading |
2017-08-16 |
|
|
| 2446 |
Abbreviations |
2017-08-16 |
|
|
| 2447 |
Conflict of Interest |
2017-08-16 |
|
|
| 2448 |
Limitations |
2017-08-16 |
|
|
| 2449 |
Case Report |
2017-08-16 |
|
|
| 2450 |
Disclosures |
2017-08-12 |
|
|
| 2451 |
Funding Source |
2017-08-12 |
|
|
| 2452 |
Acknowledgement |
2017-08-12 |
|
|
| 2453 |
Conclusion |
2017-08-12 |
|
|
| 2454 |
Keywords |
2017-08-12 |
|
|
| 2455 |
REFERENCES |
2017-08-10 |
|
|
| 2456 |
Discussion |
2017-08-10 |
|
|
| 2457 |
Results |
2017-08-10 |
|
|
| 2458 |
Materials and Methods |
2017-08-10 |
|
|
| 2459 |
Introduction |
2017-08-10 |
|
|
| 2460 |
Abstract |
2017-08-10 |
|
|